

Bamboos Health Care Holdings Limited 百本醫護控股有限公司

> ANNUAL REPORT 二零二零年報

Incorporated in the Cayman Islands with limited liability 於開曼群島註冊成立的有限公司

Stock Code 股份代號: 2293

Content

Corporate Information	2
Chairman's Statement	3
Management Discussion and Analysis	4
Corporate Governance Report	11
Environmental, Social and Governance Report	26
Biographical Details of Directors and Senior Management	43
Directors' Report	46
Independent Auditor's Report	61
Consolidated Income Statement	66
Consolidated Statement of Comprehensive Income	67
Consolidated Balance Sheet	68
Consolidated Statement of Changes in Equity	70
Consolidated Statement of Cash Flows	71
Notes to the Consolidated Financial Statements	72
Financial Summary	132

Corporate Information

BOARD OF DIRECTORS

Executive Directors

Ms Hai Hiu Chu (Chairman and Chief Executive Officer) Mr Woo King Hang (resigned on 5 July 2019)

Independent non-executive Directors

Dr Chan Kai Yue Jason Ms Chhoa Peck Lim Bella Dr Ko Wing Man Mr Wong Kon Man Jason

BOARD COMMITTEES

Audit Committee

Mr Wong Kon Man Jason (*Chairman*) Dr Chan Kai Yue Jason Ms Chhoa Peck Lim Bella

Remuneration Committee

Dr Ko Wing Man *(Chairman)* Dr Chan Kai Yue Jason (appointed on 5 July 2019) Mr Wong Kon Man Jason Mr Woo King Hang (resigned on 5 July 2019)

Nomination Committee

Ms Hai Hiu Chu *(Chairman)* Ms Chhoa Peck Lim Bella Dr Ko Wing Man

Compliance Committee

Ms Chhoa Peck Lim Bella (*Chairman*) Dr Chan Kai Yue Jason Mr Wong Kon Man Jason Mr Woo King Hang (resigned on 5 July 2019)

COMPANY SECRETARY

Ms Chan Wan Ling Sammi (appointed on 29 November 2019) Mr Yu Leung Fai (resigned on 29 November 2019)

AUTHORISED REPRESENTATIVES

Ms Hai Hiu Chu Ms Chan Wan Ling Sammi (appointed on 29 November 2019) Mr Yu Leung Fai (resigned on 29 November 2019)

AUDITOR

PricewaterhouseCoopers Certified Public Accountants Registered Public Interest Entity Auditor

LEGAL ADVISER AS TO HONG KONG LAWS

Mason Ching & Associates

REGISTERED OFFICE

PO Box 309, Ugland House Grand Cayman, KY1-1104 Cayman Islands

HEADQUARTERS AND PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Room 204, 2/F, Wing On Plaza 62 Mody Road Tsim Sha Tsui Kowloon, Hong Kong

PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE

Maples Fund Services (Cayman) Limited PO Box 1093, Boundary Hall Cricket Square, Grand Cayman KY1-1102 Cayman Islands

HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE

Union Registrars Limited Suites 3301–04, 33/F. Two Chinachem Exchange Square 338 King's Road North Point, Hong Kong

PRINCIPAL BANKERS

The Hongkong and Shanghai Banking Corporation Limited Nanyang Commercial Bank Hang Seng Bank

STOCK CODE

2293

COMPANY WEBSITE

www.bamboos.com.hk

Chairman's Statement

Dear Shareholders,

On behalf of the board of directors (the "Board" or the "Directors") of Bamboos Health Care Holdings Limited (the "Company"), together with its subsidiaries (collectively referred to as the "Group"), I am pleased to present the Group's audited annual report for the financial year ended 30 June 2020 (the "Year").

Approximately HK\$72.3 million of revenue is recorded in the Year, representing a decrease of approximately 7.9% comparing to that of approximately HK\$78.5 million recorded for the year ended 30 June 2019. Profit for the Year amounted to approximately HK\$30.7 million, representing a decrease of approximately 21.1% comparing to that of approximately HK\$38.9 million for the year ended 30 June 2019. Nevertheless, we have recorded approximately 22,000 healthcare personnel registered with the Group as at 30 June 2020 (2019: approximately 20,000) representing a 10% increase.

We believe that sustainable business requires visionary and gigantic aspiration as well as most diligent and humble execution. The Board takes initiatives from time to time to explore business opportunities and cooperate or form alliance with strategic partners to pursue new business ventures with a view to diversifying the business of the Group beyond its existing dimension and geographical location, which is in line with the Group's business strategy for sustainable development to optimise business growth and return to our stakeholders. These business endeavours in the past included the embarking on a joint venture (namely Bamboos Professional Nursing Services PTE. Limited) in Singapore with a wholly-owned subsidiary of Lippo China Resources Limited to principally engage in the provision of customised healthcare staffing solution services to individuals, institutional clients and healthcare institutions and placing of healthcare personnel on appropriate vacancies and duty assignments and the acquisition of a company, Garden Medical Centre Limited ("GMC") to explore and tap into the potential of the operation of aesthetic clinic(s) in Hong Kong. With the anticipated demands in medical aesthetic services, the Group is still confident in its potential. The Group's strong financial position also means we are well placed to continue to embark on new ventures. We will continue to seek new development and at the same time bear prudence and perseverance in mind for achieving plentiful result for all stakeholders.

Not only for business growth, but for the wellness and sustainability of the community, we take an active role during the Year in various community initiatives involving various stakeholders in the area of public health, elderly care, disadvantaged community and social diversity. With support and in-line with the Government's initiative in promotion of "ageing-in-place" and "money follows the person", the Group have also participated in the Community Care Service Voucher (CCSV) Scheme to provide assistance to elderly with needs. We aim to get "Bamboos" accessible to not only the business sector but also every community in Hong Kong.

Looking forward, not only will we keep our commitments of care and competence, as well as making progress towards our professionalism and compassion in the provision of healthcare staffing solution services and to bring sustainable growth to our shareholders' value, we also envision a continued expansion and diversification of business via new partnership.

APPRECIATION

On behalf of the Board, I would like to express my sincere gratitude to our valued customers, business partners and shareholders for their persistent support, and express my appreciation to the management team and employees for their valuable contribution to the development of the Group.

HAI Hiu Chu Chairman

Hong Kong, 18 September 2020

BUSINESS REVIEW AND PROSPECTS

The Group is dedicated to the provision of healthcare staffing solution services to individuals and institutional clients including hospitals, social service organisations and clinics in Hong Kong. The Group offers duty opportunities to self-employed healthcare personnel registered with us. Through an outreach team of healthcare professionals, the Group also provides outreach case assessment related services.

The Group's revenue for the Year was approximately HK\$72.3 million (2019: HK\$78.5 million), representing a decrease of approximately 7.9%. Profit attributable to equity holders of the Company for the Year was approximately HK\$30.7 million, representing a decrease of approximately 21.1% as compared with approximately HK\$38.9 million for the year ended 30 June 2019.

The revenue from the provision of healthcare staffing solution services for the Year was approximately HK\$66.9 million (2019: HK\$73.2 million), representing a decrease of approximately 8.6%. Though there were no material impact of COVID-19 on the Group's overall revenue, the decrease in revenue from provision of healthcare staffing solution was attributable to the entailing effects of COVID-19 on healthcare demand in the first half of 2020.

Revenue from the provision of outreach case assessment related services increased slightly by approximately HK\$0.2 million, which was mainly attributable to the increase in demand for medical and health assessment services.

To maintain a vast and diversified pool of registered healthcare personnel to better seize the opportunities for growth, the Group offered various member benefits to attract and retain healthcare personnel registered with the Group. There were approximately 22,000 healthcare personnel registered with the Group as at 30 June 2020 (approximately 20,000 as at 30 June 2019), representing an increase of approximately 10%.

In view of the ever-increasing ageing population, lightening of COVID-19, numerous on-going hospital development plans and escalating demand for services in both institutional and private healthcare staffing solution, the Board remains optimistic towards the continuous growth of the core business of the Group in the medium and long term. The Group will continue to fortify its core business and solidify its market position.

The Board takes initiatives from time to time to explore business opportunities and cooperate or form alliance with strategic partners to pursue new business ventures with a view to diversifying the business of the Group beyond its existing dimension and geographical location, which is in line with the Group's business strategy for sustainable development to optimise business growth and return to our stakeholders. These business endeavours in the past included the embarking on a joint venture (namely Bamboos Professional Nursing Services PTE. Limited) in Singapore with a wholly-owned subsidiary of Lippo China Resources Limited to principally engage in the provision of customised healthcare staffing solution services to individuals, institutional clients and healthcare institutions and placing of healthcare personnel on appropriate vacancies and duty assignments and the acquisition of a company, Garden Medical Centre Limited, to explore and tap into the potential of the operation of aesthetic clinic(s) in Hong Kong.

FINANCIAL REVIEW

Revenue

The revenue of the Group for the Year comprised revenue from (i) the provision of healthcare staffing solution services; (ii) the provision of outreach case assessment related services; and (iii) the operation of aesthetic clinic in Hong Kong. The total revenue was approximately HK\$72.3 million for the Year, representing a decrease of approximately 7.9% from approximately HK\$78.5 million for the year ended 30 June 2019.

The revenue from the provision of healthcare staffing solution services for the Year was approximately HK\$66.9 million (2019: approximately HK\$73.2 million), representing a decrease of approximately 8.6%. Among those, revenue from the institutional staffing solution services amounted to approximately HK\$37.0 million (2019: approximately HK\$39.9 million), representing a decrease of approximately 7.3%; and the revenue from the private nursing staffing services was approximately HK\$29.9 million (2019: approximately HK\$33.3 million), representing a decrease of approximately HK\$33.3 million), representing a decrease of approximately 10.2%. Due to the impact of COVID-19, the market demand for healthcare services has decreased due to the temporary shutdown of certain healthcare facilities. However, the Company had recorded a slight increase in revenue of approximately HK\$0.2 million from provision of outreach case assessment related service due to the increase of demand for medical and health assessment service.

The revenue from the provision of healthcare staffing solution services as a percentage of gross fee is determined with reference to the mark-up ratio between the charge-out rate to the clients and the pay-out rate to different ranks of healthcare personnel placed by the Group and the number of service hours performed by respective rank of healthcare personnel. The revenue from the provision of healthcare staffing solution services as a percentage of gross fee slightly increased to approximately 27.4% for the Year (2019: approximately 27.2%).

Revenue from the operation of aesthetic clinic in Hong Kong was approximately HK\$0.5 million for the Year (2019: approximately HK\$0.6 million).

Other income and other gains, net

Other income mainly include sales of goods, government grants, advertising income and rent concession. Other income increased from approximately HK\$3.3 million for the year ended 30 June 2019 to approximately HK\$5.2 million for the Year, representing an increase of approximately HK\$1.9 million or approximately 57.6%. The increase was partially contributed by the increase of sales of goods of approximately HK\$2.2 million.

Other gains, net for the Year mainly represented the net fair value gains on financial assets at fair value through profit or loss of approximately HK\$1.4 million and partially offset by net foreign exchange losses of approximately HK\$0.5 million. Other gains, net for the year ended 30 June 2019 represented the gain on deemed disposal of an associate of approximately HK\$1.9 million and gain on bargain purchase from an acquisition of business of approximately HK\$0.3 million, which offset the loss arising from misappropriation of funds of approximately HK\$1.3 million. All these gain and losses for the year ended 30 June 2019 were one-off in nature.

Expenses

The employee benefit expenses increased from approximately HK\$18.0 million for the year ended 30 June 2019 to approximately HK\$24.1 million for the Year, which was mainly attributable to the increase in headcounts of customer service and back office teams and general employee remuneration package enhancement.

The operating lease rentals and depreciation of right-of-use assets slightly decreased from approximately HK\$5.4 million for the year ended 30 June 2019 to approximately HK\$5.3 million for the Year.

Other expenses remained the same at approximately HK\$10.4 million for the Year compared with the year ended 30 June 2019.

Finance income

Finance income represented the interest income on short-term bank deposits. Finance income slightly decreased from approximately HK\$1.1 million for the year ended 30 June 2019 to approximately HK\$1.0 million for the Year.

Income tax expense

Income tax expense amounted to approximately HK\$5.5 million for the Year, representing a decrease of approximately 32.9% from approximately HK\$8.2 million for the year ended 30 June 2019. The Group's effective tax rate decreased from approximately 17.4% for the year ended 30 June 2019 to approximately 15.2% for the Year.

Profit for the Year and net profit margin

Profit for the Year amounted to approximately HK\$30.7 million (2019: approximately HK\$38.9 million), decreased by approximately 21.1%, mainly resulted from the decrease in revenue by approximately 7.9% from approximately HK\$78.5 million for the year ended 30 June 2019 to approximately HK\$72.3 million for the Year and the operating performance analysed above. The net profit margin was decreased from approximately 49.6% for the year ended 30 June 2019 to approximately 49.6% for the year ended 30 June 2019 to approximately 42.5% for the Year.

Trade receivables

Trade receivables decreased by approximately HK\$17.2 million from approximately HK\$41.4 million as at 30 June 2019 to approximately HK\$24.2 million as at 30 June 2020. The Group generally does not grant credit terms to clients and payment is immediately due upon presentation of invoices to customers. As at 30 June 2020 and 2019, all trade receivables which has past due were not considered to be impaired because these were mainly associated with a number of independent customers with limited history of default. During the Year, the Group did not recognise any provision for trade receivables (2019: Nil).

Trade payables

Trade payables decreased to approximately HK\$12.8 million as at 30 June 2020 from approximately HK\$16.3 million as at 30 June 2019, which was mainly due to the decrease in costs payable to healthcare personnel placed by the Group during the Year.

LIQUIDITY AND FINANCIAL RESOURCES

The Group remained in a healthy and sound liquidity position as at 30 June 2020. The working capital needs and other capital requirements have been met through a combination of shareholders' equity and cash generated from operations. Going forward, the Group intends to finance its future operations and capital expenditures with cash flow generated from operating activities. The primary uses of cash have been and are expected to continue to be for the purpose of operating costs and capital expenditure.

The current assets primarily include cash and cash equivalents, trade receivables, prepayments, deposits and other receivables, amounts due from related companies and inventories.

The current liabilities primarily include trade payables, lease liabilities, tax payable, accruals and other payables.

As at 30 June 2020, the Group maintained cash and cash equivalents amounting to approximately HK\$101.6 million (2019: HK\$118.7 million). Net current assets decreased to approximately HK\$105.5 million as at 30 June 2020 from approximately HK\$136.9 million as at 30 June 2019.

At 30 June 2020, the banking facilities amounting to approximately HK\$150.2 million (2019: Nil) are made available to the Group and unutilised.

FOREIGN EXCHANGE EXPOSURE RISKS

The Group's exposure to currency risk is not material. The Group mainly operates in Hong Kong with most of the operating transactions denominated and settled in Hong Kong dollars and the cash and cash equivalents of the Group are mainly denominated in Hong Kong dollars and United States dollars.

USE OF NET PROCEEDS DURING THE YEAR

The Company had, from the initial listing of the Company's shares on the Growth Enterprise Market of the Stock Exchange by way of placing (the "GEM Listing") of a total of 100,000,000 new ordinary shares of the Company at the placing price of HK\$0.5 each in 2014, raised the net proceeds of approximately HK\$39.8 million.

As at 30 June 2019, the Company had utilised approximately HK\$36.8 million of the net proceeds from the GEM Listing and approximately HK\$3.0 million remained unused (the "Remaining Net Proceeds"). Please refer to the annual report of the Company for the year ended 30 June 2019 for details.

As at 30 June 2020, the utilisation of the Remaining Net Proceeds brought forward from the previous financial year of the Company is set out below:

			Balance of Remaining	
	Remaining		Net Proceeds	
	Net Proceeds	Utilisation	to be carried	
	as at	as at	forward	
	1 July 2019	30 June 2020	(if any)	
	(HK\$ million)	(HK\$ million)	(HK\$ million)	
Strengthening brand awareness and expanding healthcare personnel pool	3.0	3.0	_	

The actual usage of the Remaining Net Proceeds during the Year was consistent with the usage as intended and previously disclosed by the Company.

During the Year, the Company had not undertaken any fund raising activity.

CAPITAL STRUCTURE

During the Year, the Group mainly relied on its equity and internally generated cash flows to finance its operations.

GEARING RATIO

Gearing ratio is calculated as net debt divided by total capital. Net debt is calculated as total borrowings less cash and cash equivalents. Total capital is calculated as "equity" (as shown in the consolidated balance sheet) plus net debt. As at 30 June 2020, the Group had a net cash position as its cash and bank balances exceeded the total borrowings by approximately HK\$95.9 million (2019: the Group had no outstanding bank and other borrowings).

CAPITAL COMMITMENTS

There were capital commitments for HK\$2.5 million to Bamboos Professional Nursing Services PTE. Limited (the joint venture company set up in Singapore) (2019: HK\$2.5 million) and approximately HK\$0.5 million for intangible assets contracted but not provided for as at 30 June 2020 (2019: approximately HK\$0.4 million for property, plant and equipment contracted but not provided for).

PLEDGE OF ASSETS

As at 30 June 2020, there was no significant pledge on the Group's assets (2019: Nil).

CONTINGENT LIABILITIES

As at 30 June 2020, the Group had a contingent liability in relation to a litigation case. Please refer to Note 38 to the consolidated financial statements for details.

FUTURE PLANS FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS

The Group did not have other plans for material investments or capital assets as at 30 June 2020 (2019: Nil).

SIGNIFICANT INVESTMENT, MATERIAL ACQUISITIONS AND DISPOSALS OF SUBSIDIARIES AND AFFILIATED COMPANIES

On 31 March 2020 and 1 April 2020, Bamboos FinTech Limited, an indirectly wholly-owned subsidiary of the Company, acquired 2,000,000 senior notes listed on the Stock Exchange with stock code: 4418 (the "Senior Notes"), and with an aggregate consideration of approximately USD1,706,000 (equivalent to approximately HK\$13,307,000) in cash on exchange. The Senior Notes have a coupon rate of 13.75% per annum distributed semi-annually with a maturity date at 11 March 2022. For further details, please refer to the Company's announcement dated 6 April 2020.

EMPLOYEES AND REMUNERATION POLICIES

As at 30 June 2020, the Group employed a total of 75 employees (2019: 52). Total staff costs including Directors' remuneration for the Year amounted to approximately HK\$24.1 million (2019: HK\$18.0 million).

The remuneration package of the employees includes salary and discretionary bonus. Employees' remuneration is determined based on the individual's qualifications, experience, position, job responsibilities and market conditions. Salary adjustments and promotion are based on evaluation of performance by way of annual review, and discretionary bonuses are paid to employees with reference to the Group's financial performance of the preceding financial year and performance of individual employees. The Group's remuneration policies are in line with the prevailing market practices.

To reward eligible participants (including but not limited to directors and employees of the Group) for their contributions to the Group and/or to incentivise or motivate them to work towards enhancing the value of the Group for its long-term growth and development for the benefit of the Company and its shareholders as a whole, the Company may from time to time grant share options pursuant to its share option scheme currently in force (which is valid and effective for a period of 10 years from 8 July 2014) to subscribe for ordinary shares in the Company. During the Year, share options were granted by the Company under the share option scheme to selected grantees to subscribe for an aggregate of 10,000,000 ordinary shares in the Company (2019: 8,000,000 ordinary shares).

DIVIDEND

On 18 September 2020, the Board resolved to recommend a final dividend of HK2.50 cents (2019: HK5.00 cents) per ordinary share for the year ended 30 June 2020 to the Company's shareholders whose names appear on the register of members of the Company on Monday, 16 November 2020. Subject to the approval of the Company's shareholders at the forthcoming annual general meeting of the Company, which is scheduled to be held on Friday, 6 November 2020 (the "AGM"), the final dividend, which is payable in cash, is expected to be paid on or about Thursday, 26 November 2020.

On 17 February 2020, the Board resolved to declare and pay an interim dividend of HK\$10,000,000 (HK2.50 cents per ordinary share) to the Company's shareholders whose names appeared on the register of members of the Company on 2 March 2020.

EVENTS AFTER THE REPORTING PERIOD AND OTHER INFORMATION

The Group has no significant events after the reporting period and up to the date of this report.

The board of directors (the "Board" or the "Directors") of the Company (together with its subsidiaries, collectively referred to as the "Group") is committed to ensuring and upholding a high standard of corporate governance, transparency and business practices, which are fundamental to achieving the Group's vision of becoming or continuing to be a leading, most respected and fast growing provider of healthcare staffing solution services in Hong Kong and safeguarding the overall interests of the Company and its shareholders (the "Shareholders").

The Company's corporate governance practices are based on the principles of the Corporate Governance Code (the "CG Code") as set out in Appendix 14 to the Rules Governing the Listing of Securities (the "Listing Rules") of The Stock Exchange of Hong Kong Limited (the "Stock Exchange"). During the year ended 30 June 2020 (the "Year") and up to the date of this report, the Company had complied with the applicable code provisions set out in the CG Code, except as disclosed in the paragraph headed "Corporate Governance" in this report below.

BOARD OF DIRECTORS

The Board is responsible for leadership and control of the Company and overseeing the management of the business and affairs of the Company. The Directors are accountable for making decisions objectively in the best interests of the Company and the Shareholders as a whole.

The day-to-day management, administration and operation of the Company are delegated to the executive Director(s), who is/are assisted by the senior management of the Group. The independent non-executive Directors are responsible for participating in Board meetings of the Company to make an independent judgement on issues of strategy, performance, resources and standards of conducts of the Group, taking the lead where potential conflicts of interest arise and serving on the audit, remuneration, nomination and/or other governance committees.

The Board is responsible for making decisions on all major aspects of our Company's affairs, including the approval and monitoring of key policy matters, overall strategies, business plans and annual budgets, internal control and risk management systems, material transactions, major capital expenditure, appointment of Directors and other significant financial and operational matters. The senior management is mainly responsible for the execution or implementation of the policy, strategies, business plans, budgets, internal control and risk management practices as may be formulated or adopted by our Board from time to time.

Board Composition

During the Year and up to the date of this report, the Board comprises the following Directors and their respective roles are set out as follows:

Executive Directors: Ms Hai Hiu Chu (Chairman and Chief Executive Officer) Mr Woo King Hang (resigned on 5 July 2019)

Independent non-executive Directors: Dr Chan Kai Yue Jason Ms Chhoa Peck Lim Bella Dr Ko Wing Man Mr Wong Kon Man Jason

Save as the relationships in the companies disclosed elsewhere in the annual report for the Year and summarised below, there are no financial, business, family or other material/relevant relationships among our Directors during the Year.

Name of company	Principal business	Nature of relationship
Bamboos Group Limited ("BGL")	Principally engaged in tenancy holding and was the head tenant of the head office and principal place of business of the Company in Hong Kong since January 2017 to October 2019 (namely, 4/F, Star House, 3 Salisbury Road, Tsim Sha Tsui, Kowloon, Hong Kong)	Business relationship – Bamboos Group Limited is directly owned as to 100% by Ms Hai Hiu Chu (a director of BGL) as at year ended 30 June 2020.
Bamboos Education – School for Talents Limited ("BEST")	Principally engaged in the provision of healthcare related training service in Hong Kong	Business relationship – BEST is directly owned as to 100% by Ms Hai Hiu Chu (a director of BEST) as at year ended 30 June 2020.

A description of the Directors is set out in the section headed "Biographical Details of Directors and Senior Management" on pages 43 to 45 in this annual report.

Chairman and Chief Executive Officer

As disclosed in this report above, Ms Hai Hiu Chu is the chairman of the Board and the chief executive officer of the Company. Ms Hai performs a leadership role in monitoring, managing and evaluating the business, strategic planning and development and major decision making of the Group.

Director's Appointments, Re-election and Removal

All the Directors, including independent non-executive Directors, are subject to retirement by rotation and eligible for re-election in accordance with the Company's articles of association. At each annual general meeting, not less than one third of the Directors then in office shall retire and every Director is subject to retirement by rotation at least once every three years.

Confirmation of Independence

Each of the independent non-executive Directors had made a confirmation of independence by reference to Rule 3.13 of the Listing Rules for relevant periods and the Board is satisfied that all the independent non-executive Directors were independent and met the independent guidelines set out in Rule 3.13 of the Listing Rules for relevant periods since the date of their respective appointments, up to the date of this annual report.

Number of Meetings and Directors' Attendance

The Board meets regularly for considering, reviewing and/or approving matters relating to, among others, the financial and operating performance, as well as, the overall strategies and policies of the Company. Additional meetings are held when significant events or important issues are required to be discussed and resolved.

As regards the meeting of the Shareholders and to comply with the requirement under Code Provision E.1.2 of the CG Code, the chairman of the Board, as well as the chairman of each of the audit, nomination, remuneration and compliance committees attended the annual general meeting of the Company held on 13 November 2019 (the "2019 AGM") to answer questions at the 2019 AGM.

The attendance records of each Director at the meetings of the Board and the Shareholders held during the Year are set out as follows:

		2019 AGM (held on
	Board	13 November 2019)
Executive Directors:		
Ms Hai Hiu Chu	6/6	1/1
Mr Woo King Hang (resigned on 5 July 2019)	0/6	0/1
Independent non-executive Directors:		
Dr Chan Kai Yue Jason	6/6	1/1
Ms Chhoa Peck Lim Bella	6/6	1/1
Dr Ko Wing Man	6/6	1/1
Mr Wong Kong Man Jason	6/6	1/1

Practice and Conduct of Meetings

The schedule and agenda of each meeting are made available to the Directors in advance such that each Director is given an opportunity to provide his/her input to the agenda items. Advance notice of at least 14 days is given for a regular Board meeting. For other Board and committee meetings, reasonable notices are generally given.

Minutes of all Board meetings recording sufficient details of matters considered and decisions reached are circulated to the Directors and open for inspection by the Directors.

The Company's articles of association contain provisions requiring Directors to abstain from voting and not to be counted in the quorum at meetings for approving transactions in which such Directors or any of their associates have a material interest.

Board papers together with all appropriate, complete and reliable information are sent to all Directors well in advance before each Board meeting or Board committee meeting to keep the Directors appraised of the latest developments of the Group and financial position of the Company and to enable them to make informed decisions.

BOARD COMMITTEES

Audit Committee

The Board established the audit committee on 24 June 2014 with written terms of reference (updated on 1 January 2019) which are of no less exacting terms than those set out in the CG Code. The full terms of reference setting out details of duties of the audit committee are available on the Stock Exchange's website at www.hkexnews.hk and the Company's website at www.bamboos.com.hk.

As at 30 June 2020, the audit committee comprised three independent non-executive Directors, namely Dr Chan Kai Yue Jason, Ms Chhoa Peck Lim Bella and Mr Wong Kon Man Jason. Mr Wong Kon Man Jason was the chairman of the audit committee during the Year.

The primary duties of the audit committee are to oversee the Company's financial reporting system, risk management and internal control systems, make recommendations to the Board on the appointment, re-appointment and removal of the external auditors and to approve their terms of engagement and remuneration, review and monitor the external auditor's independence and objectivity and the effectiveness of the audit process in accordance with applicable standards, meet with external auditor regularly and provide advice and recommendations to the Board.

During the Year, the audit committee had reviewed the interim and annual consolidated financial statements of the Group, and was satisfied that the accounting policies and standards of the Group complied with the applicable accounting standards and requirements and that adequate disclosures have been made. Also, the audit committee oversees the effectiveness and objectivity of the systems of risk management and internal controls, and the audit process.

Two audit committee meetings were held during the Year. The attendance records of individual committee members are set out below:

	Number of Meetings
	attended/eligible to attend
Mr Wong Kon Man Jason	2/2
Dr Chan Kai Yue Jason	2/2
Ms Chhoa Peck Lim Bella	2/2

Remuneration Committee

The Board established the remuneration committee on 24 June 2014 with written terms of reference (updated on 1 March 2017) which are of no less exacting terms than those set out in the CG Code. The full terms of reference setting out details of duties of the remuneration committee are available on the Stock Exchange's website at www.hkexnews.hk and the Company's website at www.bamboos.com.hk.

As at 30 June 2020, the remuneration committee comprised three independent non-executive Directors, namely Dr Chan Kai Yue Jason, Dr Ko Wing Man and Mr Wong Kon Man Jason. Dr Ko Wing Man was the chairman of the remuneration committee during the Year.

The primary duties of the remuneration committee are to make recommendations to the Board on the overall remuneration policy and structure relating to all Directors and senior management of the Group, review and approve the management's remuneration proposals, and ensure that none of the Directors determine his/her own remuneration.

The remuneration committee determines Directors' remuneration by reference to the benchmarking of the market. The Company also looks into individual Director's competence, duties, responsibilities, performance and the results of the Group in determining the exact level of remuneration for each Director. During the Year, the remuneration committee had reviewed and made recommendations to the Board on the remuneration packages of the Directors based on the outcome of the review conducted by the remuneration committee.

Details of the remuneration of the Directors and the five highest paid individuals are set out in Note 11 to the consolidated financial statements.

One remuneration committee meeting was held during the Year. The attendance records of individual committee members are set out below:

	Number of Meetings
	attended/eligible to attend
Dr Ko Wing Man	1/1
Dr Chan Kai Yue Jason	1/1
Mr Wong Kon Man Jason	1/1
Mr Woo King Hang (resigned on 5 July 2019)	0/1

Nomination Committee

The Board established the nomination committee on 24 June 2014 with written terms of reference (updated on 1 March 2017) which are of no less exacting terms than those set out in the CG Code. The full terms of reference setting out details of duties of the nomination committee are available on the Stock Exchange's website at www.hkexnews.hk and the Company's website at www.bamboos.com.hk.

As at 30 June 2020, the nomination committee comprised one executive director, namely Ms Hai Hiu Chu, and two independent non-executive Directors, namely Ms Chhoa Peck Lim Bella and Dr Ko Wing Man. Ms Hai Hiu Chu was the chairman of the nomination committee during the Year.

The primary function of the nomination committee is to make recommendations to the Board regarding appointment of Directors and candidates to fill vacancies on the Board.

The Board adopted the board diversity policy in accordance with the requirement as set out in the CG Code. The Board recognises the benefits of having a diverse Board and considers a number of factors which include but are not limited to age, gender, professional experience, cultural and education background as to its composition. The nomination committee regularly monitors and reviews the implementation and the effectiveness or appropriateness of the Board diversity policy.

During the Year, the nomination committee had reviewed the structure, size and composition of the Board, the independence of independent non-executive Directors and the appointment of Directors of the Company.

Two nomination committee meetings were held during the Year. The attendance records of individual committee members are set out below:

	Number of Meetings
	attended/eligible to attend
Ms Hai Hiu Chu	2/2
Ms Chhoa Peck Lim Bella	2/2
Dr Ko Wing Man	2/2

Board diversity policy

On 31 December 2018, the nomination committee recommended to the Board and the Board approved and adopted a board diversity policy for the Company, a summary of which is set out below:

- 1. the Company is committed to equality of opportunity in all aspects of its business and does not discriminate on the grounds of race, gender, disability, nationality, religious or philosophical belief, age, sexual orientation, family status or any other factor;
- 2. the Company believes that a diversity of perspectives can be achieved through consideration of a number of factors, including skills, regional and industry experience, professional experience, background, education, race, gender, age, culture and other qualities etc.;
- 3. the Company endeavours to ensure that its Board has the appropriate balance of skills, experience and diversity of perspectives that are required to support the execution of its business strategy and to maximise the Board's effectiveness;
- 4. appointments of members of the Board will continue to be made on a merit basis and candidates will be considered against objective criteria, with due regard for the benefits of diversity on the Board; and
- 5. the Board will review the board diversity policy on a regular basis to ensure its continued effectiveness.

During the Year, the nomination committee had reviewed the board diversity policy and considered that the implementation of board diversity policy was adequate and effective.

Nomination policy

To ensure the composition of the Board has a balance of skills, experience and diversity of perspectives appropriate to the requirements of the Company's business, the Company has, with the recommendation of the nomination committee, adopted a formal, considered and transparent procedures for the selection, appointment and re-appointment of Directors. The nomination committee has been delegated to identify individuals suitably qualified to become Board members and select or make recommendations to the Board on the selection of individuals nominated for directorships.

Nomination procedures

The nomination committee utilises various methods for identifying director candidates, including recommendations from Board members, management, and professional search firms. In addition, the nomination committee will consider director candidates properly submitted by the Shareholders.

All director candidates, including incumbents and candidates nominated by the Shareholders are evaluated by the nomination committee based upon the director qualifications, as summarised below. While director candidates will be evaluated on the same criteria, the nomination committee retains the discretion to establish the relative weighting of such criteria, which may vary based on the composition, skill sets, and experiences of the collective Board rather than on the individual candidate.

The evaluation of director candidates may include, without limitation, the following:

- review of resume and job history;
- personal interviews;
- verification of professional and personal references; and
- performance of background checks.

The Board will consider the recommendations of the nomination committee and is responsible for designating the director candidate(s) to be considered by the Shareholders for their election at the general meeting of the Company, or appointing the suitable candidate to act as Director to fill the Board vacancies subject to compliance of the constitutional documents of the Company.

All appointments of director(s) should be confirmed by letter of appointment and/or service contract setting out the key terms and conditions of the appointment of the Directors.

Selection criteria

The criteria to be taken into account when considering the suitability of a candidate will be whether a candidate has the qualifications, skills and experience, gender diversity, etc. that can add to and complement the range of skills, experience and background of existing Directors, in particular, the following:

- the highest personal and professional ethics and integrity;
- proven achievement and competence in the nominee's field and the ability to exercise sound business judgement;
- skills that are complementary to those of the existing Board;
- the ability to assist and support management and make significant contributions to the Company's success; and

• an understanding of the fiduciary responsibilities that is required of a member of the Board and the commitment of time and energy necessary to diligently carry out those responsibilities.

Compliance Committee

The Board established the compliance committee on 24 June 2014. As at 30 June 2020, the compliance committee comprised three independent non-executive Directors, namely Dr Chan Kai Yue Jason, Ms Chhoa Peck Lim Bella and Mr Wong Kong Man Jason. Ms Chhoa Peck Lim Bella was the chairman of the compliance committee during the Year.

The primary functions of the compliance committee include, among others, reviewing and making recommendations to the Board in respect of the compliance of the Group's policies and practices with any requirement, direction and regulation as may be prescribed by the Board from time to time, contained in any constitutional documents applicable to the Group, or imposed by the applicable laws, regulations, rules and codes (including but not limited to the Listing Rules for relevant periods), and ensuring that appropriate monitoring systems are in place to ensure compliance against the relevant internal control systems, processes and policies, and monitoring the implementation of the Group's plan to maintain high compliance with own risk management standards.

During the Year, the compliance committee had reviewed the Group's compliance with the Listing Rules, the Companies Ordinance, the Competition Ordinance and other applicable laws, regulations, rules and codes of the Company. The compliance committee also reviewed the policies and practices regarding the training and continuous professional development, as well as the code of conduct and compliance of the Directors regarding securities transaction.

One compliance committee meeting was held during the Year. The attendance records of individual committee members are set out below:

	Number of Meetings attended/eligible to attend
Ms Chhoa Peck Lim Bella	1/1
Dr Chan Kai Yue Jason	1/1
Mr Wong Kon Man Jason (appointed on 9 January 2019)	1/1
Mr Woo King Hang (resigned on 5 July 2019)	0/1

SENIOR MANAGEMENT'S REMUNERATION

Senior management's remuneration payment of the Group for the year ended 30 June 2020 falls within the following band:

Number	of	individu	alc
number	UI.	muiviuu	ais

Nil to HK\$1,000,000

2

DIVIDEND POLICY

On 31 December 2018, the Board adopted a new dividend policy of the Company. Under the dividend policy:

- 1. the Company considers stable and sustainable returns to shareholders of the Company to be its goal and endeavours to maintain a dividend policy to achieve such goal. In deciding whether to propose a dividend and in determining the dividend amount, the Board will take into account the Group's results of operations, earnings performance, cashflows, financial condition, future prospects, as well as statutory and regulatory restrictions on the payment of dividends, and other factors that the Board may consider relevant.
- 2. Whilst the Board will review from time to time for determination on any proposed dividend with the above factors taken into account, there can be no assurance that dividends will be declared or paid in any particular amount for any given period.

CORPORATE GOVERNANCE FUNCTIONS

The Board is responsible for performing the functions specified in Code Provision D.3.1 of the CG Code, which include reviewing the Company's corporate governance policies and practices, the continuous training and professional development of the Directors and senior management, the Company's policies and practices on compliance with legal and regulatory requirements and the Company's compliance with the CG Code and disclosure in this Corporate Governance Report.

During the Year, the Board had reviewed the Company's policies and practices on corporate governance.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the "Model Code") as set out in Appendix 10 to the Listing Rules as the code for securities transactions by Directors. The Directors, after specific enquires by the Company, confirmed their compliance with the required standards set out in the Model Code throughout the Year.

CORPORATE GOVERNANCE

The Board is committed to ensuring and upholding a high standard of corporate governance, transparency and business practices, which are fundamental to achieving the Group's vision of becoming or continuing to be a leading, most respected and fast growing provider of healthcare staffing solution services in Hong Kong and safeguarding the overall interests of the Company and its shareholders (the "Shareholders").

The Company's corporate governance practices are based on the principles of the Corporate Governance Code (the "CG Code") as set out in Appendix 14 to the Listing Rules. During the Year and up to the date of this report, the Company had complied with the applicable code provisions set out in the CG Code, except for the deviation from Code Provision A.2.1 which is explained below.

Code Provision A.2.1

Under Code Provision A.2.1, the roles of the chairman and the chief executive officer should be segregated and should not be performed by the same individual.

Since 18 August 2018, Ms Hai Hiu Chu ("Ms Hai") acted as the chairman of the Board and the chief executive officer of the Company. Ms Hai is the founder of the Group and has extensive experience in the medical field and the pharmaceutical industry. Ms Hai is responsible for the effective running of the Board and for formulating business strategies. The Board considers that Ms Hai, by serving as the chairman of the Board and the chief executive officer of the Company, is able to lead the Board in major business decision making for the Group. The management structure enables the Board's decision to be more effectively made and facilitates the implementation of business strategies under the leadership of Ms Hai, which is conducive to the effective management and the business development of the Group.

The Board will continue to review the effectiveness of the Group's corporate governance structure to assess whether changes, including the separation of the roles of the chairman and the chief executive officer, are necessary.

DIRECTORS' CONTINUOUS TRAINING AND PROFESSIONAL DEVELOPMENT

Pursuant to Code Provision A.6.5 of the CG Code, all Directors should participate in continuous professional development to develop and refresh their knowledge and skills. This is to ensure that their contribution to our Board remains informed and relevant.

During the Year, all Directors (namely Ms Hai Hiu Chu, Mr Woo King Hang, Dr Chan Kai Yue Jason, Ms Chhoa Peck Lim Bella, Dr Ko Wing Man and Mr Wong Kon Man Jason) participated in the continuous professional developments regarding the duties and responsibility of the Directors under the relevant legal and regulatory requirement which included reading materials in relation to directors' liability and insurance and other legal or regulatory update. All Directors have participated in training regarding the Listing Rules and the CG Code updates conducted by the Company Secretary during the Year.

CONSTITUTIONAL DOCUMENTS

During the Year, there were no changes in any of the Company's constitutional documents. The latest version of the Company's constitutional documents is available on the Stock Exchange's website at www.hkexnews.hk and the Company's website at www.bamboos.com.hk.

AUDITOR'S REMUNERATION

The remuneration paid/payable to the auditor of the Company during the Year is set out as follows:

Services rendered during the Year

Statutory audit services

800

HK\$'000

DIRECTORS' RESPONSIBILITY STATEMENT

The Board is responsible for the preparation of the financial statements. In preparing the financial statements, the generally accepted accounting standards in Hong Kong have been adopted, appropriate accounting policies have been used and applied consistently, and reasonable and prudent judgements and estimates have been made. Having made appropriate enquiries, the Board is not aware of any material uncertainties relating to events or conditions which may cast significant doubt over the Group's ability to continue as a going concern. Accordingly, the Board has continued to adopt the going concern basis in preparing the financial statements.

RISK MANAGEMENT AND INTERNAL CONTROLS

The Board has overall responsibility for the adequacy and effectiveness of the risk management and internal control systems of the Group. The Board has developed its systems of internal control and risk management to safeguard the interests of the Shareholders and the assets of the Group. Such systems are designed to manage rather than eliminate the risk of failure to achieve business objectives, and can only provide reasonable and not absolute assurance against material misstatements or losses.

The Group has engaged an external professional consultant (the "Internal Control Consultant") to conduct an independent internal control review for the year ended 30 June 2020 and the review is completed as at the date of this annual report.

The main features of the risk management and internal control systems are described below:

Risk Management System

The Group adopts a risk management system which manages the risk associated with our business and operations and compliance with applicable laws and regulations. The system comprises the following phases:

- Identification: Identify the category and ownership of risks, risks that could affect the achievement of objectives and the risk appetite.
- Assessment: Analyse the likelihood and impact of risks and evaluate the risk portfolio semi-annually.
- Management: Consider the risk action plan, ensure effective communication to the Board and on-going monitoring.

Internal Control System

The Company has in place an internal control system devised, recommended and/or reviewed by the Internal Control Consultant who reported directly to the Audit Committee. The system covers mainly, amongst all, the effectiveness and efficiency of operations and reliability of accounting and financial reporting.

The Group's internal control system comprises an established organisational structure and comprehensive policies and working procedures. Areas of responsibilities of each department are reasonably defined to ensure sufficient segregation of duties.

The key procedures that the Board established to provide effective controls are as follows:

- a distinct organisational structure exists with defined lines of authority and control responsibilities;
- a comprehensive management accounting system is in place to provide financial and operational performance information to the management and the relevant financial information for reporting and disclosure purpose; and
- the Audit Committee reviews recommendations submitted by the Internal Control Consultant and the external auditors annually to the Group's management in connection with the internal review exercise and annual audit respectively.

Internal control in relation to insider information

In order to enhance the Group's system of handling inside information, and to ensure the truthfulness, accuracy, completeness and timeliness of the public disclosures, the Group adopts and implements an inside information/price sensitive information disclosure policy.

Certain reasonable measures have been taken from time to time to ensure that proper safeguards exist to prevent a breach of a disclosure requirement in relation to the Group, which include:

- Employees who are in possession of inside information are fully conversant with their obligations to preserve confidentiality.
- Confirmation on commitment to non-disclosure of the received information and undertaking of not to deal in the Company's securities are in place when any external parties who may become privy to or in possession of the Company's unpublished inside information/price sensitive information respectively.
- Only authorised persons shall explain information already in the public domain, and shall avoid giving answers which individually or cumulatively may provide unpublished or potential inside information/price sensitive information to the receiving party.

During the Year, the Board had adopted a risk management system policy and assessment plan and conducted a review of the adequacy and effectiveness of the risk management and internal control systems which covered all material controls, including financial, operational and compliance controls and risk managements functions of the Group. There was no significant control deficiency identified and the Board considered the risk management and internal control systems effective and adequate.

COMPANY SECRETARY

All Directors have access to the advice and services of the Company Secretary to ensure that the Board procedures and all applicable laws are followed. Moreover, the Company Secretary is responsible for facilitating communications among Directors as well as with the management. The company secretary of the Company, Ms Chan Wan Ling Sammi ("Ms Chan") (appointed on 29 November 2019) and Mr Yu Leung Fai (resigned on 29 November 2019), is delegated by an external service provider. The external service provider's primary contact person at our Company is Ms Hai Hiu Chu, the Chief Executive Officer of the Company. The biographical details of Ms Chan are set out under the section headed "Biographical Details of Directors and Senior Management". Ms Chan has confirmed that she has undertaken no less than 15 hours of professional training to update her skills and knowledge during the Year.

PROCEDURES FOR SHAREHOLDERS TO CONVENE AN EXTRAORDINARY GENERAL MEETING

According to article 12.3 of the Company's articles of association, two or more Shareholders (or a Shareholder who is a recognised clearing house (or its nominee(s)) (the "Requisitionists"), holding not less than 10% of the paid-up capital of the Company can convene an extraordinary general meeting (the "EGM") by depositing a requisition (the "Requisition") in writing to the Directors or the Company Secretary for the purpose of requiring the convening of the EGM. The written requisition shall be deposited to the Company's principal place of business at Room 204, 2/F, Wing On Plaza, 62 Mody Road, Tsim Sha Tsui, Kowloon, Hong Kong or through email at the e-mail address designated by the Company from time to time and marked for the attention of the Board of Directors/Company Secretary.

If the Board does not within 21 days from the date of deposit of the Requisition proceed duly to convene the meeting to be held, within a further 21 days, the Requisitionists themselves or any of them representing more than one-half of the total voting rights of all of them, may convene the general meeting in the same manner, as nearly as possible, as that in which meetings may be convened by the Board provided that any meeting so convened shall not be held after the expiration of three months from the date of deposit of the Requisition, and all reasonable expenses incurred by the Requisitionists as a result of the failure of the Board in convening the meeting shall be reimbursed to them by the Company.

PROCEDURES FOR SHAREHOLDERS TO PUT FORWARD PROPOSALS AT SHAREHOLDERS' MEETINGS

To put forward proposals at a general meeting of the Company, a Shareholder should lodge a written notice of his/her/ its proposal (the "Proposal") with his/her/its detailed contact information at the Company's office at Room 204, 2/F, Wing On Plaza, 62 Mody Road, Tsim Sha Tsui, Kowloon, Hong Kong.

Upon confirming the Proposal is proper and in order by the Company's branch share registrar in Hong Kong, the Board will determine in its own discretion whether the Proposal may be included in the agenda for general meeting. The notice period to be given to all the Shareholders for consideration of the Proposal at the general meeting varies from 14 to 21 clear days and not less than 10 or 20 clear business days depending on the nature of the Proposal and the nature of the general meeting (annual or extraordinary).

COMMUNICATION WITH SHAREHOLDERS

The Company endeavors to maintain an on-going dialogue with the Shareholders and in particular, through annual general meetings or other Shareholders' meetings to communicate with the Shareholders and encourage their participation. The Company updates the Shareholders on its latest business developments and financial performance through its annual and interim reports. The corporate website of the Company (http://www.bamboos.com.hk) has provided an effective communication platform to the public and the Shareholders through regularly updating its "Investor Relations" section.

The Company will ensure that there are separate resolutions for separate issues proposed at all the Shareholders' meetings.

The Company will continue to maintain an open and effective investor communication policy and to update investors on relevant information on the Group's business in a timely manner, subject to relevant regulatory requirements.

Shareholders should direct their questions about their shareholdings, share transfer, registration and payment of dividend to the Company's branch share registrar in Hong Kong, details of which are as follows:

Attention:	Union Registrars Limited
Address:	Suites 3301–04, 33/F., Two Chinachem Exchange Square, 338 King's Road, North Point, Hong Kong
Telephone no.:	(852) 2849 3399
Fax no.:	(852) 2849 3319

Shareholders are encouraged to communicate with the Company for requesting publicly available information and any enquiries in relation to the Group:

Attention:	The Company Secretary
Address:	Room 204, 2/F, Wing On Plaza, 62 Mody Road, Tsim Sha Tsui, Kowloon, Hong Kong
Email:	financial@bamboos.com.hk
Telephone no.:	(852) 2575 5617
Fax no.:	(852) 2575 5836

Detailed procedures for Shareholders to propose a person for election as a Director are available on the Company's website.

Hong Kong, 18 September 2020

ABOUT THIS REPORT

Bamboos Health Care Holdings Limited (the "Company"), together with its subsidiaries (collectively referred to as the "Group"), is pleased to present the 2020 Environmental, Social and Governance Report (the "Report") to provide an overview of the Group's management of significant issues affecting the operation, including environmental, social and governance issues. This Report is prepared by the Group with the professional assistance of APAC Compliance Consultancy and Internal Control Services Limited.

Preparation Basis and Scope

This Report is prepared in accordance with Appendix 27 to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") (the "Listing Rules") – "Environmental, Social and Governance Reporting Guide" and has complied with "comply or explain" provision in the Listing Rules.

This Report summarises the performance of the Group in respect of corporate social responsibility, covering its operating activities which are considered as material by the Group – provision of healthcare staffing solution services to individuals and institutional customers in Hong Kong. With the aim to optimise and improve the disclosure requirements in the Report, the Group has taken the initiative to formulate policies, record relevant data as well as implement and monitor measures. This Report shall be published both in Chinese and English on the website of the Stock Exchange. Should there be any discrepancy between the Chinese and the English versions, the English version shall prevail. The Board of Directors of the Company confirmed that during the reporting period, the Company complied with the applicable provisions contained in the "Environmental, Social and Governance Reporting Guide" of the Listing Rules.

Reporting Period

This Report demonstrates our sustainability initiatives during the reporting period from 1 July 2019 to 30 June 2020.

Contact Information

The Group welcomes your feedback on this Report for the sustainability initiatives. Please contact it by email to contact@bamboos.com.hk.

INTRODUCTION

The Group is dedicated to the provision of healthcare staffing solution services to individuals and institutional clients including hospitals, social service organisations and clinics in Hong Kong. With approximately 22,000 qualified healthcare personnel registered under the Group as at 30 June 2020, it serves as a trusted strategic advisor to provide the clients with the most comprehensive, professional and reliable services. Services offered by healthcare personnel include healthcare institution support and private nursing solutions.

Bamboos embraces the Three Cs core values – Care, Competence and Commitment. The Group is committed to the standards of service excellence and dedicated to exceeding the expectations of those it serves. In addition, it seeks to build a professional team with a positive contribution to the society, for which the business and future success will depend on. With the aim to build a healthy community, the Group devotes substantial effort to advance the quality of health care services and promote public awareness about health issues.

Sustainable development is an integral part of the Group's business strategy in order to achieve business excellence and enhance capabilities for long-term competitiveness. The Group is committed to maintaining its operation in a manner that is economically, environmentally and economically sustainable while balancing the interests of our stakeholders and fostering a positive impact on the society. The Chief Executive Officer ensures that the operation is in a responsible and sustainable manner and monitors the progress on related activities. The Group has established and implemented various policies to manage and monitor the risks related to the environment, employment, operating practices and community. Details of the management approaches to sustainable development of different areas are illustrated in this Report.

STAKEHOLDER ENGAGEMENT

The Group understands the success of the Group's business depends on the support from its key stakeholders, who (a) have invested or will invest in the Group; (b) have the ability to influence the outcomes within the Group; and (c) are interested in or affected by or have the potential to be affected by the impact of the Group's activities, products, services and relationships. This allows the Group to understand risks and opportunities. The Group will continue to ensure effective communication and maintain good relationship with each of its key stakeholders.

Stakeholders are prioritised from time to time in view of the Group's roles and duties, strategic plan and business initiatives. The Group engages with its stakeholders to develop mutually beneficial relationships and to seek their views on its business proposals and initiatives as well as to promote sustainability in the marketplace, workplace, community and environment.

The Group acknowledges the importance of intelligence gained from the stakeholders' insights, inquiries and continuous interest in the Group's business activities. The Group has identified key stakeholders that are important to the business and established various channels for communication. The following table provides an overview of the Group's key stakeholders, and various platforms and methods of communication which are used to reach, listen and respond to stakeholders.

Stakeholders	Expectations	Engagement Channels
Government	 Compliance with the laws and regulations Proper tax payment Promotion of regional economic development and employment 	 Corporate events Annual and interim reports and other published information
Shareholders and Investors	 Low risk Return on the investment Information disclosure and transparency Protection of interests and fair treatment of shareholders 	 Annual general meeting and other shareholder meetings Corporate events Annual and interim reports and other published information Website of the Company and the Stock Exchange, respectively
Employees	 Working environment Career development opportunities Self-actualization Health and safety 	 Training, seminars, briefing sessions Cultural activities Intranet and emails
Clients	 Compliance with the laws and regulations High-quality services Stable relationship Information transparency Integrity Business ethics 	 Website, brochures, annual and interim reports and other published information Email and customer service hotline Social communication channels Feedback forms Magazines (BamBoOs!Life)
Healthcare Personnel	Career opportunitiesStable relationship	SeminarsExhibitionsCorporate events
Peer and Industry Associations	Experience sharingCorporationsFair competition	 Industry seminars Exhibitions Corporate events Website of the Company
Public and Communities	Community involvementSocial responsibilities	VolunteeringCharity and social initiatives

Through general communication with stakeholders, the Group understands the expectations and concerns from stakeholders. The feedbacks obtained allow the Group to make more informed decisions, and to better assess and manage the resulting impact.

The Group have adopted the principle of materiality in the ESG reporting by understanding the key ESG issues that are important to the business of the Group. All the key ESG issues and key performance indicators (KPIs) are reported in the Report according to recommendations of the ESG Reporting Guide (Appendix 27 of the Listing Rules) and the guidelines of Global Reporting Initiative ("GRI").

The Group has evaluated the materiality and importance in ESG aspects through the following steps:

Step 1: Identification – Industry Benchmarking

- Relevant ESG areas were identified through the review of relevant ESG reports of the local and international industry peers.
- The materiality of each ESG area was determined based on the importance of each ESG area to the Group through internal discussion of the management and the recommendation of ESG Reporting Guide (Appendix 27 of the Listing Rules).

Step 2: Prioritization – Stakeholder Engagement

• The Group discussed with key stakeholders on key ESG areas identified above to ensure all the key aspects were covered.

Step 3: Validation – Determining Material Issues

• Based on the discussion with key stakeholders and internal discussion among the management, the Group's management ensured all the key and material ESG areas, which were important to the business development, were reported and in compliance with ESG Reporting Guide.

As a result of this process carried out in 2020, those important ESG areas to the Group were discussed in this Report.

A. ENVIRONMENTAL ASPECTS

A1. EMISSIONS

Environmental consideration remains one of the key focuses in fulfilling the obligation to both the environment and community. The Group is committed to continuously improving its sustainability performance by establishing relevant emission reduction and energy saving initiatives to manage its emissions and maintain green operation. The Group has implemented a "Environmental Policy" which outlines the environmental objectives and targets of the Group.

During the reporting period, the Group was not aware of any specific laws and regulations that had significant impact on the Group related to air and greenhouse gas emissions, discharges into water and land, generation of hazardous and non-hazardous waste.

Air Pollutants Emission

The operation of the Group is mainly office-based and it is not involved in the combustion of stationary sources. The air pollutants emitted by the Group are mainly generated from the company's vehicles. The Group encourages employees to adopt alternative communication means, such as telephone conferences and video conferences, to reduce air pollutants emission that arise from additional traffic. The air pollutant emission remained stable in 2020 as the revenue of the Group remained steady during the year. During the reporting period, the air pollutants emission was as follows:

Type of air pollutants	Unit	2020	2019
Nitrogen oxides (NO _x)	kg	1.56	1.60
Sulphur oxides (SO _x)	kg	0.03	0.03
Particulate matter (PM)	kg	0.12	0.12

Greenhouse Gas ("GHG") Emission

GHG is considered as one of the major contributors to the climate change and global warming. During the operation of the Group, electricity and fuel consumptions account for a major part of its GHG emission. In an effort to minimise the carbon footprint, the Group is devoted to maintaining an efficient and effective use of resources by adopting energy-saving initiatives which will be further elaborated in the section "Use of Resources" of this Report. The GHG scope 1 and scope 3 emissions in 2020 were similar to those of last year, which was in line with the stable revenue of the Group during the year. The decrease in GHG scope 2 emission in 2020 was owing to the effective implementation of electricity saving policies during the year as well as better utilization of staff-to-office space ratio which entailed a more focused and effective electricity consumption.

During the reporting period, the GHG emission was as follows:

Type of GHG emission	Unit	2020	2019
Scope 1 ¹	tonnes of CO ₂ -e	5.24	5.26
Scope 2 ²	tonnes of CO ₂ -e	27.78	90.92
Scope 3 ³	tonnes of CO ₂ -e	0.12	0.11
Total GHG emission	tonnes of CO ₂ -e	33.14	96.29
GHG emission intensity	tonnes of CO ₂ -e/revenue in HK\$'000	0.0004	0.0012

¹ Scope 1: Direct emission from sources that are owned or controlled by the Group.

² Scope 2: Indirect emissions from the generation of purchased electricity consumed by the Group.

³ Scope 3: All other indirect emissions that occur outside the Group, including emissions from paper waste disposal and the electricity used for fresh water processing and sewage processing.

Hazardous and Non-hazardous Wastes

Regarding the business nature of the Group, it does not generate any hazardous waste. The non-hazardous waste is generated from the office operation and is considered as insignificant to the Group's business. In spite of this, the Group endeavours to reduce the amount of waste and strengthen the environmental awareness of the employees.

In order to reduce paper waste, the Group introduced paper consumption reduction initiatives and promoted recycling of paper. Employees are encouraged to use double sides of paper and recycled paper. Besides, the Group reduced the thickness of printing paper from 80gsm to 70gsm as an initiative to reduce paper consumption. The Group has also implemented recycling scheme for paper waste. In light of the effective implementation of waste reduction strategies, the amount of non-hazardous waste decreased slightly during the year.

As the Group is only involved in office operation, water discharge from office use is systematically collected by building sewage system and treated in sewage treatment plant. Besides, the office solid waste is properly collected and handled by a cleaning company engaged by property management department. The discharges into water and land is relatively small and insignificant to the Group's business.

The wastes generated by the Group, which mainly consist of paper waste, during the reporting period were summarised as follows:

Wastes	Unit	2020	2019
Non-hazardous waste generated	tonnes	0.081	0.091
Non-hazardous waste generated intensity	tonnes/employee	0.002	0.003
Non-hazardous waste recycled	tonnes	0.081	0.091
Non-hazardous waste recycled intensity	tonnes/employee	0.002	0.003

A2. USE OF RESOURCES

The Group places great emphasis on ensuring efficient use of resources. It strives to promote resource saving by adopting green office practices and motivating the employees to participate in resource conservation activities. It has incorporated the guidelines of using resources efficiently into the staff handbook in order to enhance their environmental awareness.

Energy

The energy consumption of the Group comes from purchased electricity for premises operation and fuel used by the Company's vehicles. In order to reduce the energy consumption, the Group advocated various energy conservation strategies. The Group has implemented lighting zone control and adopted efficient lamps in the office.

By posting energy-saving notices, employees are reminded to switch off the electrical appliance when they are not in use. Besides, room temperature is maintained at an energy-efficient level of 25 degrees Celsius and monitored by designated personnel. The petrol consumption remained stable in 2020 due to slight reductions in vehicle usage during the year. With the effective implementation of electricity saving policies by the Group, the electricity consumption reduced accordingly during the year.

During the reporting period, the energy consumption was as follows:

Type of energy	Unit	2020	2019
Purchased electricity	MWh	55.57	178.27
Petrol	MWh	17.19	17.26
Total energy consumption	MWh	72.76	195.53
Energy consumption intensity	MWh/revenue in HK\$'000	0.0010	0.0025

Water

Water is another important resource. The water it used by the Group is supplied by Water Supplies Department. The Group strives to reduce water consumption by strengthening the water-saving awareness of the employees. It reminds the employee to conserve water by emails and posting signs. The stable water consumption in 2020 was mainly owing to the steady growth of the Group during the year. During the reporting period, the total water consumption was as follows:

Water	Unit	2020	2019
Total water consumption	m ³	194.95	189.98
Water consumption intensity	m³/revenue in HK\$'000	0.0026	0.0024

A3. THE ENVIRONMENT AND NATURAL RESOURCES

Regarding the business nature of the Group, it is not aware of any significant impact of the business activities on the environment and natural resources. With the implementation of "Environmental Policy" and aforementioned green office practices to reduce air pollutants and GHG emissions, waste generation and resources consumption, the Group strives to enhance environmental sustainability and minimise the impacts on the environment.

B. SOCIAL ASPECTS

EMPLOYMENT AND LABOUR PRACTICES

B1. EMPLOYMENT

The Group believes people are the most valuable assets and resources to the continuing development and success of the Group. It strives to construct a working environment where the employees can demonstrate their capabilities, create values and achieve comprehensive development.

The staff handbook covers the Group's standard in respect of compensation and dismissal, recruitment and promotion, working hours, rest periods and other benefits and welfare. The Group is in strict compliance with the Employment Ordinance (Cap. 57).

The Group strives to construct a diverse and inclusive workplace where all its employees are treated with dignity and respect. The Group adheres to the principles of fairness in all aspects of employment and strictly prohibits all forms of discrimination or harassment against any individual on the basis of seniority, nationality, gender, age, marital status, disability, race, colour, religion or sexual preference. The Group participates in the Hong Kong government's "Talent-Wise Employment Charter and Inclusive Organisations Recognition Scheme", where it supports disabled people in unleashing their potential and create an inclusive working environment.

Remuneration and employee benefits are crucial to retain and motivate employees in achieving key objectives of the Group. It provides competitive remuneration and benefits for the employees in accordance with the Employment Ordinance (Cap. 57). The Group offers a five-day work week, medical insurance and mandatory provident fund ("MPF") to the employees. It is recognised as a "Good MPF Employer" by the Mandatory Provident Fund Schemes Authority. Employees are also entitled to various leaves, such as paid annual leave, sick leave and maternity and paternity leave. The Group also provides a fresh supply of snacks, fruits and drinks for the employees. Recognising the importance of a work-life balance to a motivated and productive workforce, it organises recreational activities, such as birthday celebrations, Christmas and spring dinners, seafood feast and health seminars to create a relaxing working environment and enrich the staff relations.

During the reporting period, the Group was not aware of any non-compliance with the relevant laws and regulations that had significant impact on the Group relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination and other benefits and welfare.

As at 30 June 2020, the employee compositions (in numbers of employees) by gender, employment category, age group and geographical region were as follows:



The employee annual turnover rate by gender, age group, geographical region during the reporting period was as follows:

Employment	2020
By gender	
• Male	67%
• Female	30%
By age group	
• 30 or below	92%
• 31–40	-
• 41–50	40%
• 51 or above	67%
By geographical region	
• Hong Kong	41%
Overall	41%

B2. HEALTH AND SAFETY

Given the nature of the business operation, chances of occupational accidents are comparatively lower than other industries. In spite of this, the Group places the highest priority on securing health and safety of the employees. The Group is in strict compliance with the Occupational Safety and Health Ordinance (Cap. 509) and strives to provide and maintain a safe and hygienic working environment for the employees to protect them from work-related injuries. The "Guidelines on Occupational Health and Safety" covers potential hazards in the office and guidelines to minimise the potential health and safety risks. Below are some of the examples:

Lighting

Sufficient lightings in the workplace enable employees to recognise hazards and reduce visual strain. Louver or diffuser is installed for fluorescent lights to control the distribution of light. To reduce glare and screen reflection, daylight may be shielded by blinds or curtains.

Indoor Air Quality and Ventilation

Efficient ventilation can provide a comfortable working environment and avoid invisible health hazard. The Group prohibits smoking within the office area. Air outlets are cleaned on a regular basis to improve the indoor air quality and increase the efficiency of the ventilation system. Air purifier are also placed at each department to enhance air quality.

Working Posture

The Group provides employees with adjustable chairs and encourage them to pay attention to their usual sitting posture to reduce stress and strain on their bodies. In addition, soft chair pads for posture are available to all staff to provide extra support to minimise back-pain.

During the reporting period, there was no work-related fatality or injury. The Group was not aware of any noncompliance with the relevant laws and regulations that had significant impact on the Group in providing a safe and healthy working environment during the reporting period.

B3. DEVELOPMENT AND TRAINING

The Group considers the skills and knowledge of its employees as the key elements of the Group's continued business growth and success. With the implementation of the "Training Policies", it encourages the employees to participate in training programs to enhance their skills and competencies to meet the business needs and personal growth.

For newly recruited employee, the Group provides induction orientation, which covers corporate culture and responsibilities of the position. For existing employees, the Group provides various training opportunities, covering complaint handling procedures, branding and customer service, healthcare and nursing knowledge, etc.

During the reporting period, the percentage of employees trained and the average training hours by gender are as follows:

Percentagehoursof employees(hours/Gendertrainedemployee)			Average training
		Percentage	hours
Gender trained employee)		of employees	(hours/
	Gender	trained	employee)
Male 100% 67.5	Male	100%	67.5
Female 100% 72.0	Female	100%	72.0
Overall 100% 91.1	Overall	100%	91.1

B4. LABOUR STANDARDS

With the implementation of the Group's "Labour Standards Policy", the Group is committed to supporting the effective abolition of child labour and upholding the elimination of all forms of compulsory labour. The Group adheres to the relevant laws and regulations, including the Employment Ordinance (Cap. 57) and strictly prohibits recruitment of children aged under 15. During the recruitment process, applicants are required to present their identity documents to Human Resources Department for age verification as prevention of engaging child labour. Besides, all work should be performed on a voluntary basis. Working hours and rest periods are stipulated in the staff handbook.

During the reporting period, the Group was not aware of any non-compliance with relevant laws and regulations related to recruitment of child labour or forced labour practices.

OPERATING PRACTICES

B5. SUPPLY CHAIN MANAGEMENT

The Group mainly cooperates with third-party services providers such as information technology service, property management service, advertising service, legal and consulting service. The Group also works with suppliers which supply office equipment, printing and stationery to it.

With its "Green Procurement Policy" covering guidelines in making sustainable procurement decisions, the Group strives to promote and support the environmental initiatives in the supply chain. The Group has priority in procuring products that with greater energy efficiency, recyclable and with less packaging materials, in order to reduce the environmental impacts.

B6. PRODUCT RESPONSIBILITY

The Group regards service quality as one of the key competitive advantages of the business. It continues to provide highquality services in order to meet the expectations of the clients and enhance their satisfaction. The Group adheres with the Personal Data (Privacy) Ordinance (Cap. 486), the Books Registration Ordinance (Cap. 142) and the Trade Description Ordinance (Cap. 362).

Quality Management System

In order to maintain the high-quality services, the Group has established the training manual which covers the customer service procedures. The Group ensures that the employees are familiarise with the work procedures in order to deliver standardised and high-quality services.

In addition, to ensure healthcare personnel registered under Bamboos are qualified to deliver high-quality services, the Group has a stringent healthcare personnel registration procedure. It conducts interviews with healthcare personnel and requires them to provide relevant certifications and employment proofs.

Complaints Handling Management System

The Group believes the opinions from the clients are valuable input for its continuous improvement and vital to its pursuit for excellence. The Group conducts customer satisfaction survey and phone interview regularly to monitor client satisfaction and understand their needs for our continuous improvement.

The Group is committed to the efficient and fair resolution of all complaints. The "Complaint Handling Policy" outlines the Group's complaint handling process. In the receipt of complaints, the relevant information including the description of complaint, the requested remedy and the action taken, will be recorded immediately. The Group will then assess its severity and investigate the complaints thoroughly. Following the investigation, it will contact the complainant and provide the complainant with a response and remedy.

With the "Complaints Handling Procedures", the Group ensures that employees are adequately trained and provided with sufficient support to handle complaints appropriately. Training is provided at the induction stage for all employees and will be updated and reinforced as necessary.

Personal Data Privacy and Protection

The Group is aware of the importance in handling personal information. It takes high precaution in ensuring its confidentiality to avoid misuse or leakage of personal data. It has engaged an independent information technology consultant under a service agreement which specifies that information and data must be managed with strict care to restrict any unauthorised access and avoid careless leakage. Besides, its internal server system and customer relationship management system are restricted with different access levels. Employees can only access to certain data on a "need-to-know" basis in order to reduce the risk of data leakage.

The Group has incorporated its requirements in relation of confidentiality into staff handbook and employment contracts. Employees are required to fully abide by the guidance on prohibiting any unauthorised disclosure of confidential information. Besides, it conducts exit interviews with leaving employees to emphasise the importance of confidential data protection after the termination of employment and requires them to be aware of by signing a declaration.

Intellectual Property Rights

The Group has always attached great importance to the protection of the intellectual property rights by ensuring necessary filing or registration. The Group has registered its logos and its representing cartoon characters.

Advertising

The Group ensures that information for service introduction is real. All external advertisements were produced in accordance with the relevant request and scope of legislations. They would only be put on the websites and other advertising platforms after being reviewed by the Group's management.

Labelling

The Group mainly provides health care services, which do not involve any labeling issues relating to the services provided.

During the reporting period, the Group was not aware of any non-compliance with the relevant laws and regulations that had significant impact on the Group relating to health and safety, advertising, labelling and privacy matters relating to services provided and methods of redress.

B7. ANTI-CORRUPTION

The Group is committed to upholding high standards of business ethics and integrity. The Group strictly complies with the Prevention of Bribery Ordinance (Cap. 201) and forbids any form of corruption, extortion, bribery, fraud, money laundering and embezzlement. As stipulated in the staff handbook, Directors and employees shall not solicit or accept any banquets, gifts, rebate or other forms of bribing benefits for the sake of relation, influence, interests or activities that could compromise the best interest of the Group.

The Group's "Whistle-blowing Policy" allows whistleblowers to report any unlawful conduct, any incident of corruption, avoidance of internal controls, incorrect or improper financial or other reporting to the management by the compliance hotline. The case of suspected corruption will be handled in an unbiased and confidential manner.

During the reporting period, our Group was not aware of any non-compliance with the relevant laws and regulations that had significant impact on the Group relating to bribery, extortion, fraud and money laundering except for the incident regarding a subsidiary's misappropriation of funds disclosed in Note 38 to the Consolidated Financial Statements in the Annual Report. There was no legal case regarding corrupt practices brought against the Group during the reporting period.

COMMUNITY

B8. COMMUNITY INVESTMENT

As a socially responsible enterprise, the Group is constantly aware of the community needs and strives to bring a positive impact on community development. The Group has been a Caring Company of Hong Kong Council of Social Service's Caring Company Scheme since the Group's establishment. The Group continue to participate in various community activities concerning public health, elderly care, healthcare professional development and social diversity and inclusion. It encourages service to the community through staff voluntary efforts and in-kind donations.

Our Group supports community development by cash donation and in-kind donation. During the reporting period, it made cash donation to various charitable organisations and sponsored charity activities with in-kind donation. In support for the healthcare professional and personnel amidst COVID-19, the group has also organised various free gift events for its members.

Nature of support	2020	2019
	HK\$'000	HK\$'000
Cash sponsorship	70	66
Sponsorship in-kind to:	69	49
 Sponsoring gift bags and lucky draw gifts to activities 		
 Supporting charity sales 		
Volunteering in initiatives		
• Support in promotion and media		
Support in event management		
Total	139	115

In addition, the Group encourages its employees to dedicate their time and skills to participate in different voluntary activities and support local community. During the reporting period, it initiated and participated in various volunteer programmes in supporting community development with the aim to create a harmonious community.

The following table shows some more events organized by the Group during the reporting period.

Event
Free words for all tasks
Free masks for elderly
Free gift pack for healthcare personnel
National Nurse day – Free gift pack and masks
Fight the influenza (齊心抗流感): free gift – Vitamin D tablets
Fight the influenza (齊心抗流感): free gift – Propolis
Free community influenza vaccination programs (免費社區流感疫苗)
Flag day (Regeneration Society)
Ocean Park day trip with elders

ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORTING INDEX

Subject ar	eas, aspects, general disclosures and		
Key Perfor	mance Indicators (KPIs)	Section	Pages
A. Environ	mental		
A1: Emissi	ons		
General Di	isclosure	"Emissions"	30
KPI A1.1	The types of emissions and respective emissions data	"Emissions – Air Pollutant Emissions"	30
KPI A1.2	Greenhouse gas emissions in total and, where appropriate, intensity	"Emission – Greenhouse Gas Emissions"	30
KPI A1.3	Total hazardous waste produced and, where appropriate, intensity	"Emissions – Hazardous and Non- hazardous Wastes"	31
KPI A1.4	Total non-hazardous waste produced and, where appropriate, intensity	"Emissions – Hazardous and Non- hazardous Wastes"	31
KPI A1.5	Description of measures to mitigate emissions and results achieved	"Emissions – Greenhouse Gas Emissions"	30
KPI A1.6	Description of how hazardous and non-hazardous wastes are handled, reduction initiatives and results achieved	"Emissions – Hazardous and Non- hazardous Wastes"	31
A2: Use of	Resources		
General Di	isclosure	"Use of Resources"	32
KPI A2.1	Direct and/or indirect energy consumption by type in total and intensity	"Use of Resources – Energy"	32
KPI A2.2	Water consumption in total and intensity	"Use of Resources – Water"	32
KPI A2.3	Description of energy use efficiency initiatives and results achieved	"Use of Resources – Energy"	32

Subject areas, aspects, general disclosures and

Key Perfor	mance Indicators (KPIs)	Section	Pages
KPI A2.4	Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency initiatives and results achieved	"Use of Resources – Water"	32
KPI A2.5	Total packaging material used for finished products and, if applicable, with reference to per unit produced	Not applicable to our Group's business.	N/A
ኣ3: The En	vironment and Natural Resources		
General Di	sclosure	"The Environment and Natural Resources"	33
KPI A3.1	Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them	No significant impact of activities on the environment and natural resources was noted.	N/A
B. Social			
	nt and Labour Practices		
31: Employ			
General Di		"Employments"	33-34
(PI B1.1	Total workforce by gender, employment type, age group and geographical region	"Employments"	33-34
KPI B1.2	Employee turnover rate by gender, age group and geographical region	"Employments"	35
B2: Health	and safety		
General Di	sclosure	"Health and Safety"	35
KPI B2.1	Number and rate of work-related fatalities	-	35
KPI B2.2	Lost days due to work injury	-	_
KPI B2.3	Description of occupational health and safety measures adopted, how they are implemented and monitored	"Health and Safety"	35
B3: Develo	pment and Training		
General Di	sclosure	"Development and Training"	36
KPI B3.1	The percentage of employee trained by gender and employee category	"Development and Training"	36
KPI B3.2	The average training hours completed per employee by gender and employee category	"Development and Training"	36
34: Labour	Standards		
General Di		"Labour Standards"	36
KPI B4.1	Description of measures to review employment practices to avoid child and forced labour	"Labour Standards"	36
KPI B4.2	Description of steps taken to eliminate such practices when discovered	-	-

Key Perfo	rmance Indicators (KPIs)	Section	Pages
Operating	Practices		
	v Chain Management		
General Di	-	"Supply Chain Management"	37
KPI B5.1	Number of suppliers by geographical region	_	_
KPI B5.2	Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, how they are	_	_
	implemented and monitored		
B6: Produc	t Responsibility		
General D	isclosure	"Product Responsibility"	37
KPI B6.1	Percentage of total products sold or shipped subject to recalls for safety and health reasons	-	-
KPI B6.2	Number of products and service related complaints received and how they are dealt with	_	-
KPI B6.3	Description and practices relating to observing and protecting intellectual property rights	-	_
KPI B6.4	Description of quality assurance process and recall procedures	_	-
KPI B6.5	Description of consumer data protection and privacy policies, how they are implemented and monitored	_	_
B7: Anti-co	orruption		
General Di	isclosure	"Anti-corruption"	38
KPI B7.1	Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the case	No concluded legal case regarding corrupt practices was noted.	_
KPI B7.2	Description of preventive measures and whistle- blowing procedures, how they are implemented and monitored	-	_
Communit	у		
B8: Comm	unity Investment		
General Di	isclosure	"Community Investment"	39
KPI B8.1	Focus areas of contribution (e.g. education, environmental concerns, labour needs, health, culture, sport)	"Community Investment"	39
KPI B8.2	Resources contributed (e.g. money or time) to the focus area	"Community Investment"	39

Biographical Details of Directors and Senior Management

EXECUTIVE DIRECTOR

Ms Hai Hiu Chu, aged 49, is an executive Director, the Chief Executive Officer and the controlling shareholder of the Company. Ms Hai is appointed as the Chairman of the Board with effect from 18 August 2018. Ms Hai co-founded the Group in May 2009. She was appointed as a Director on 23 November 2012 and redesignated as an executive Director on 28 March 2014. Ms Hai is responsible for the overall management, strategic development and major decision making for our Group.

Ms Hai obtained a bachelor's degree in Chinese Medicine and a master's degree of Chinese Medicine from The University of Hong Kong in November 2008 and November 2012 respectively. She has also completed a programme in EMBA and obtained a master's degree in Business Administration from The Chinese University of Hong Kong in December 2010. She obtained an EN qualification from the Nursing Council of Hong Kong in February 1993. Ms Hai has over 22 years of experience in the medical field and the pharmaceutical industry. From September 2005 to April 2009, Ms Hai was a managing director of Bamboos Limited.

Ms Hai currently serves as the chairman of Hong Kong Health Care Federation, a member of Registration Committee of Chiropractors Council; and a visiting professor of Guangdong Pharmaceutical University. Also, Ms Hai is the winner of the Most Promising Entrepreneurship Award in Asia Pacific Entrepreneurship Awards 2012.

INDEPENDENT NON-EXECUTIVE DIRECTORS

Dr Chan Kai Yue Jason, JP, aged 46, is an independent non-executive Director and a member of the audit committee, remuneration committee and compliance committee. Dr Chan has extensive experience in education and information technology industries. Dr Chan has been the Head of Information Technology of the College of Professional and Continuing Education (CPCE) at the Hong Kong Polytechnic University since July 2010.

Dr Chan graduated from City University of Hong Kong with a Bachelor of Arts in Public and Social Administration with First Class Honours in 1998. He further obtained a Master of Science degree in Computing at City University of Hong Kong in 2004 and a Master of Educational Technology degree at The University of British Columbia in 2005. He completed the Stanford Certified Project Manager certificate program in Stanford University in 2007 and his doctorate in Doctor of Education at The University of Bristol in 2010.

Dr Chan has been appointed in several public services. He is currently serving as a member of the Dissemination and Promotion Sub-committee of the Quality Education Fund for Education Bureau, a member of Property Management Services Authority, a lay member of the Solicitors Disciplinary Tribunal of Judiciary Hong Kong, a member of the Transports Tribunals Panel for Transport and Housing Bureau, a member of Advisory Committee of the Innovation and Technology Venture Fund (ITVF) for Innovation and Technology Bureau, a member of the Steering Committee of Child Development Fund for Labour and Welfare Bureau, a co-opted member of Consumer Council and a member of the Entrepreneurship Committee Advisory Group for Hong Kong Cyberport. Dr Chan was appointed as Justice of the Peace of Hong Kong on 30 June 2017.

Biographical Details of Directors and Senior Management

Ms Chhoa Peck Lim Bella, aged 50, is an independent non-executive Director, the chairman of the compliance committee and a member of the audit committee and nomination committee. Ms Chhoa is currently the director of leasing & management of Hang Lung Properties Limited overseeing its Hong Kong leasing portfolio since July 2017 and served as a director of corporate affairs, general counsel and company secretary of Hang Lung Group Limited (stock code: 10) and Hang Lung Properties Limited (stock code: 101) from August 2011 to July 2017 overseeing their legal, company secretarial and human resources matters. Prior to joining Hang Lung Group Limited and Hang Lung Properties Limited (stock code: 330) from July 2008 to August 2011. Ms Chhoa has extensive experience in general management, legal, company secretarial and human resources matters gained in blue-chip listed companies.

Ms Chhoa is a solicitor qualified to practice in Hong Kong. She graduated from the University of Hong Kong with a Bachelor degree in Law in 1992. Ms Chhoa also obtained an Executive Master of Business Administration degree from the Chinese University of Hong Kong in 2004.

Dr Ko Wing Man, GBS, BBS, JP aged 63, is an independent non-executive Director, the chairman of the remuneration committee and a member of the nomination committee. Dr Ko is an orthopaedic surgeon. Dr Ko holds the degrees of Bachelor of Medicine and Bachelor of Surgery from the University of Hong Kong in 1981. He received a Fellowship from the Royal College of Surgeons of Edinburgh, the United Kingdom in 1986 and was awarded a degree of Master of Health Administration from The University of New South Wales, Australia in 1993. He became a Fellow of the Hong Kong Academy of Medicine in the specialty of Orthopaedic Surgery and Hong Kong College of Community Medicine in Administrative Medicine in 1993 and 2000, respectively. In 2002, he became Fellow of the Faculty of Public Health Medicine of the Royal Colleges of Physicians of the United Kingdom. Dr Ko is an independent non-executive director of The People's Insurance Company (Group) of China Limited (stock code: 1339).

Dr Ko was the Secretary for Food and Health of the Government of Hong Kong Special Administrative Region from July 2012 to June 2017. He is a member of the 13th National Committee of the Chinese People's Political Consultative Conference. He was appointed as Justice of the Peace in 2001 and was awarded the Bronze Bauhinia Star and Gold Bauhinia Star by the Government of Hong Kong in 2008 and 2017, respectively.

Mr Wong Kon Man Jason, aged 56, is an independent non-executive Director, the chairman of the audit committee and a member of the remuneration committee and compliance committee. Mr Wong graduated from the University of Hawaii at Manoa in the United States with a bachelor's degree in business administration (majoring in accountancy) in 1988. He has over 25 years of experience in finance and investment. He was a financial consultant for Transpac Capital Ltd. from 1993 to 2000. He has been the managing director of Fortune Capital Group Limited since 2000. He is also one of the founding members and an investment committee member of Whiz Partners Asia Ltd.. He is a member of American Institute of Certified Public Accountants and Hong Kong Institute of Certified Public Accountants.

Mr Wong was an independent non-executive director of Ascent International Holdings Limited (stock code: 264) from 2017 to 2018; an independent non-executive director of China Lending Corporation Ltd. (Nasdaq: CLDC) from 2016 to 2017; an independent non-executive director of DT Asia Investments Ltd. (Nasdaq: CADTU) from 2014 to 2016; an independent non-executive director of Group Sense (International) Limited (currently known as Rare Earth Magnesium Technology Group Holdings Limited) (stock code: 601) from 2014 to 2015; an independent non-executive director of Neo-Neon Holdings Limited (stock code: 1868) from 2011 to 2014 and an independent non-executive director of Polyard Petroleum International Group Limited (stock code: 8011) from 2010 to 2013.

Biographical Details of Directors and Senior Management

SENIOR MANAGEMENT

Ms Lui Yin Ping, aged 48, is the senior general manager (customer service) of the Group. Ms Lui joined the Group in July 2009, and is responsible for the supervision of operation and performance of the Customer Service Department. Ms Lui obtained an Executive Secretarial Diploma from Professional of Career Youth Department of Hong Kong Young Women's Christian Association in October 1996. She has over 25 years of experience in the customer service field. Prior to joining our Group, she worked in various positions relating to customer relations in Reader's Digest Association Far East Limited, a publisher from June 1995 to February 2008, where she was mainly responsible for handling customer inquiries and complaints and assisting the manager to carry out the customer loyalty program. From April 2008 to June 2009, Ms Lui worked as a customer service executive of Bamboos Limited, responsible for providing general customer services.

COMPANY SECRETARY

Ms Chan Wan Ling Sammi, aged 34, is a practising solicitor admitted in the Hong Kong Special Administrative Region and a member of the Law Society of Hong Kong. She has also been a Certified Management Accountant since 2016 and a Lawyer of the Supreme Court of New South Wales since 2014. Ms Chan has a Postgraduate Certificate in Laws and a Bachelor of Laws degree from the City University of Hong Kong and a Bachelor of Business Administration in Accounting and Finance degree from the University of Hong Kong. Ms Chan has not held any directorships in any listed company over the past three years.

The directors of the Company (the "Directors" or the "Board") are pleased to present to the shareholders their annual report together with the audited consolidated financial statements for the year ended 30 June 2020.

PRINCIPAL ACTIVITIES

The principal activity of the Company is investment holding. The principal activities of the Company's principal subsidiaries are set out in Note 37 to the consolidated financial statements. There were no significant changes in the nature of the Group's principal activities during the Year.

BUSINESS REVIEW

A fair review of the business of the Group as required under Schedule 5 to the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) comprising analysis of the Group's performance during the Year, assessment of the principal risks and uncertainties faced by the Group, particulars of important events affecting the Group that have occurred subsequent to the end of the Year, as well as indication of likely future development in the business of the Group are set out in the sections headed "Chairman's Statement" on page 3 and "Management Discussion and Analysis" on pages 4 to 10.

Discussions on the environmental policies and performance, compliance by the Group with the relevant laws and regulations that have a significant impact on the Group and the account of the key relationships of the Group with our stakeholders are contained in the "Environmental, Social and Governance Report" on pages 26 to 42.

RESULTS AND APPROPRIATIONS

The Group's results for the year ended 30 June 2020 and the state of affairs of the Company and the Group at that date are set out in the consolidated financial statements on pages 66 to 131.

On 18 September 2020, the Board resolved to declare a final dividend of HK\$10,000,000 (HK2.50 cents per ordinary share) for the year ended 30 June 2020 (2019: HK5.00 cents per ordinary share, totally HK\$20,000,000) to the Company's shareholders whose names appear on the register of members of the Company on 16 November 2020.

On 17 February 2020, the Board resolved to declare and pay an interim dividend of HK\$10,000,000 (HK2.50 cents per ordinary share) for the six months ended 31 December 2019 to the Company's shareholders whose names appear on the register of members of the Company on 2 March 2020.

SUMMARY OF FINANCIAL INFORMATION

A summary of the results, assets and liabilities of the Group for the last five financial years, as extracted from the published audited financial statements and restated/reclassified as appropriate, is set out on page 132. This summary does not form part of the audited consolidated financial statements.

PROPERTY, PLANT AND EQUIPMENT

Details of movements in the property, plant and equipment of the Group during the Year are set out in Note 16 to the consolidated financial statements.

BANK BORROWING

There was no bank borrowing maintained by our Group as at 30 June 2020 (2019: Nil).

SHARES IN ISSUE IN THE YEAR

Details of the ordinary shares (the "Shares") of HK\$0.01 each in issue in the Year are set out in Note 26 to the consolidated financial statements.

DISTRIBUTABLE RESERVES

As at 30 June 2020, our Company's reserves available for distribution, calculated in accordance with the Companies Law, Cap. 22 (Law 3 of 1961, as consolidated and revised) of the Cayman Islands, amounted to approximately HK\$10,123,000 (2019: HK\$20,056,000).

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

Neither the Company nor any of its subsidiaries had purchased, redeemed or sold any of the Company's listed securities during the Year and up to the date of this report.

DIRECTORS

The Directors of the Company during the Year and up to the date of this report were:

Executive Directors

Ms Hai Hiu Chu (Chairman and Chief Executive Officer) Mr Woo King Hang (resigned on 5 July 2019)

Independent non-executive Directors

Dr Chan Kai Yue Jason Ms Chhoa Peck Lim Bella Dr Ko Wing Man Mr Wong Kon Man Jason

Biographical details of the Directors and the senior management of the Group are set out on pages 43 to 45 of this annual report.

All the Directors, including non-executive and independent non-executive Directors, are subject to retirement by rotation and eligible for re-election in accordance with the Company's articles of association. At each annual general meeting, not less than one third of the Directors then in office shall retire and every Director is subject to retirement by rotation at least once every three years.

Mr Woo King Hang resigned as executive Director of the Company with effect from 5 July 2019. He has confirmed that he has no disagreement with the Board and nothing relating to the affairs of the Company needed to be brought to the attention of the Shareholders of the Company.

Confirmation of Independence

Each independent non-executive Director has given the Company an annual confirmation of independence pursuant to Rule 3.13 of the Listing Rules for relevant periods. The Company considers that all the independent non-executive Directors are independent and meet the independent guidelines set out in Rule 3.13 of the Listing Rules for relevant periods.

DIRECTORS' SERVICE CONTRACTS

None of the Directors has a service contract with the Company or any of its subsidiaries which is not determinable by the employer within one year without payment of compensation (other than statutory compensation).

DIRECTORS' AND CONTROLLING SHAREHOLDERS' MATERIAL INTERESTS IN TRANSACTIONS, ARRANGEMENTS AND CONTRACTS

Except for the transactions disclosed in Note 34 to the consolidated financial statements, no transactions, arrangements and contracts of significance in relation to the Group's business to which the Company's subsidiaries, fellow subsidiaries or its parent companies was a party and in which a Director or his or her connected party had a material interest, whether directly or indirectly, subsisted at the end of the Year or at any time during the Year.

COMPETING INTERESTS OF DIRECTORS, CONTROLLING SHAREHOLDERS AND THEIR RESPECTIVE CLOSE ASSOCIATES

Save as disclosed in this annual report and summarised below, none of the Directors, controlling shareholders of the Company or their respective close associates (as defined under the Listing Rules) had any business or interest in a business which competes or may compete with the business of the Group and any other conflict of interest with the Group throughout the Year.

Name of company	Shareholding in the company attributable to the Directors or controlling shareholders	Nature of business	Remarks
Bamboos Medicine Limited ("BML")	100% by Ms Hai Hiu Chu	Provision of Chinese medicine consultation and treatment services in Hong Kong	Ms Hai Hiu Chu is a director of BML
Bamboos Education – School for Talents Limited ("BEST")	100% by Ms Hai Hiu Chu	Provision of healthcare related training service in Hong Kong	Ms Hai Hiu Chu is a director of BEST

COMPLIANCE WITH NON-COMPETITION UNDERTAKINGS BY THE CONTROLLING SHAREHOLDERS

Pursuant to the deed of non-competition undertaking dated 21 February 2017 (the "DNU") given by, among others, the controlling shareholders of the Company (namely, Ms Hai Hiu Chu and Gold Empress Limited) (the "Controlling Shareholders") in favour of the Company (for itself and as trustee for and on behalf of each of its subsidiaries) and save and except for those exceptions as expressly stated in the DNU, the Controlling Shareholders have jointly and severally, unconditionally and irrevocably covenanted and undertaken, among other things, to the Company (for itself and as trustee for and on behalf of each of its subsidiaries) various non-competition and other undertakings, including but not limited to the undertakings not to, and to procure that none of their respective associates (as defined in the Listing Rules and other than members of the Group) will during the period during which (a) the Company's shares remain listed on the Stock Exchange; and (b) the Controlling Shareholders and their respective associates (other than members of the Group), individually or jointly, are entitled to exercise, or control the exercise of, not less than 30% of the voting power at general meetings of the Company; or (c) the Controlling Shareholders or the relevant associates remain as a director of any member of the Group, directly or indirectly, either on their own account, in conjunction with, on behalf of, or through any person, entities, organisations, firm or company, among other things:

- (i) carry on, participate or be interested, engaged or otherwise involved in or acquire or hold (in each case whether as an investor, a shareholder, partner, agent or otherwise and whether for profit, reward or otherwise) any business (including but not limited to the core business in Hong Kong (namely the provision of healthcare staffing solution services but excluding the businesses operated by BML and BEST as disclosed in this annual report above) which is or is likely to be in competition with the core business of the Group, and any other new business that the Group may undertake from time to time after its listing on the Stock Exchange (the "Restricted Business") and where they become aware of such engagement of the Restricted Business they shall notify the Company forthwith;
- (ii) without the consent from the Company, make use of any information pertaining to the business of the Group which may have come to its knowledge in its capacity as its controlling shareholders for any purpose of engaging, investing or participating in any Restricted Business; and
- (iii) if there is any project or new business opportunity that relates to the Restricted Business, each of them will refer such project or new business opportunity to the Group for consideration.

The Controlling Shareholders had also continued to uphold, among others, their undertaking by allowing the Company and its representatives to have access to such information, financial and/or corporate records to facilitate the Company to determine the compliance of the undertakings contained in the DNU during the Year.

The Controlling Shareholders have provided to the Company a written confirmation confirming that, during the Year, they and their respective associates have complied with the undertakings contained in the DNU, and that there is no matter in relation to their compliance with or enforcement of the DNU that needs to be brought to the attention of the Stock Exchange, the Company and/or the Shareholders. The independent non-executive Directors have also confirmed to the Company that, having made such reasonable enquiries with the Controlling Shareholders and reviewed such documents as they considered appropriate, nothing has come to their attention that causes them to believe that the terms of the DNU had not been complied with by the Controlling Shareholders during the Year.

DIRECTORS' AND CHIEF EXECUTIVES' INTERESTS AND/OR SHORT POSITIONS IN THE SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ITS ASSOCIATED CORPORATIONS

As at 30 June 2020, the interests and short positions in the shares, underlying shares and debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (the "SFO")) held by the Directors and chief executives of the Company which have been notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which were taken or deemed to have under such provisions of the SFO), or have been notified to the register maintained by the Company pursuant to section 352 of the SFO, or otherwise have been notified to the Company and the Stock Exchange pursuant to the Model Code as set out in Appendix 10 to the Listing Rules were as follows:

(1) Long position in the ordinary shares (each a 'Share') of HK\$0.01 each in the Company

			Percentage of
		Number of	shareholding
Name of Director	Nature of interest	Shares held	(Note 2) (%)
Ms Hai Hiu Chu	Interest of a controlled corporation	270,000,000	67.50%
		(Note 1)	

Notes:

- 1. Ms Hai Hiu Chu is deemed to be interested in the 270,000,000 Shares held by Gold Empress Limited ("Gold Empress") by virtue of the SFO as Gold Empress is wholly owned by Ms Hai Hiu Chu.
- 2. All the interests stated above represent long positions. The percentage of shareholding is calculated on the basis of 400,000,000 Shares in issue as at 30 June 2020.

(2) Interests in share options granted by the Company under its share option scheme

Name of Director	Date of grant	Exercise period	Exercise price per Share	Number of underlying share	Approximate percentage of shareholding % (Note 3)
Ms Hai Hiu Chu	29/04/2019 26/06/2020	Note 1 Note 2	HK\$1.440 HK\$0.994	1,850,000 2,000,000	0.463% 0.500%
Mr Wong Kon Man Jason	29/04/2019 26/06/2020	Note 1 Note 2	HK\$1.440 HK\$0.994	250,000 300,000	0.063% 0.075%
Ms Chhoa Peck Lim Bella	26/06/2020	Note 2	HK\$0.994	300,000	0.075%
Dr Chan Kai Yue Jason	26/06/2020	Note 2	HK\$0.994	300,000	0.075%

Notes:

- 1. 50% of the share options shall be vested from 30 April 2020 to 29 April 2029 (both dates inclusive) and 50% of the share options shall be vested from 30 April 2021 to 29 April 2029 (both dates inclusive), being Type 1 Share Options referred to in the Company's announcement dated 29 April 2019. For details, please refer to the section "Share Option Scheme" in this report.
- 50% of the share options shall be vested from 27 June 2021 to 26 June 2030 (both dates inclusive), 50% of the share options shall be vested from 27 June 2022 to 26 June 2030 (both dates inclusive). For details, please refer to the section "Share Option Scheme" in this report.
- 3. The percentage of shareholding is calculated on the basis of 400,000,000 Shares in issue as at 30 June 2020.

Save as disclosed above, none of the Directors and chief executives of the Company had an interest or short position in the shares, underlying shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which were taken or deemed to have under such provisions of the SFO), or which were required to be entered in the register maintained by the Company pursuant to section 352 of the SFO, or which were required to be notified to the Company and the Stock Exchange pursuant to the Model Code as set out in Appendix 10 to the Listing Rules.

SUBSTANTIAL SHAREHOLDERS' INTERESTS AND/OR SHORT POSITIONS IN THE SHARES AND UNDERLYING SHARES OF THE COMPANY

So far as the Directors are aware, as at 30 June 2020, other than the Directors and chief executives of the Company, the following persons/entities had interests or short positions in the shares or underlying shares of the Company which were required to be disclosed to the Company under Divisions 2 and 3 of Part XV of the SFO or which were required to be recorded in the register required to be kept under section 336 of the SFO:

Name of shareholder	Capacity	Number of Shares held	Percentage of shareholding (Note 3) (%)
Gold Empress	Beneficial owner	270,000,000 (Note 1)	67.50%
HRnetGroup Limited (Note 2)	Beneficial owner	32,000,000	8.00%

Notes:

- 1. Under the SFO, Ms Hai Hiu Chu is deemed to be interested in the 270,000,000 Shares held by Gold Empress by virtue of her holding of the entire issued share capital of Gold Empress.
- 2. HRnetGroup Limited is a corporation incorporated in Singapore whose issued shares are listed on the Main Board of the Singapore Exchange Securities Trading Limited.
- 3. All the interests stated above represent long positions. The percentage of shareholding is calculated on the basis of 400,000,000 Shares in issue as at 30 June 2020.

Save as disclosed above, as at 30 June 2020, no other persons/entities had any interests or short positions in the shares or underlying shares of the Company which were required to be disclosed to the Company under Divisions 2 and 3 of Part XV of the SFO or which were required to be recorded in the register of the Company required to be kept under section 336 of the SFO.

SHARE OPTION SCHEME

The Company's share option scheme (the "Share Option Scheme") was conditionally approved and adopted by a resolution of the shareholders of the Company passed on 24 June 2014 and became unconditional upon the date of the Company's initial listing of its Shares on GEM (that is 8 July 2014) (the "Listing Date").

The purpose of the Share Option Scheme is to reward eligible participants who have contributed to the Group and to encourage them to work towards enhancing the value of the Company and the Shares for the benefit of the Company and the Shareholders as a whole.

The Directors may, at their discretion, offer options (the "Options" or "share options") to subscribe for such number of Shares in accordance with the terms set out in the Share Option Scheme to the following eligible participants: directors (including executive Directors, non-executive Director and independent non-executive Directors) and employees of the Group and any advisers, consultants, distributors, contractors, suppliers, agents, customers, partners, joint venture business partners, promoters or service providers of any member of the Group who the Board considers, in its sole discretion, have contributed or will contribute to the Group.

The maximum number of Shares which may be issued upon exercise of all Options to be granted under the Share Option Scheme and any other share option schemes of the Company shall not, in the absence of Shareholders' approval, in aggregate exceed 40,000,000 Shares (the "General Scheme Limit"), being 10% of the aggregate number of 400,000,000 Shares in issue on the Listing Date. As at the date of this annual report, the total number of Shares that remained available for issue under the General Scheme Limit was 24,590,000 Shares, representing approximately 6.15% of the issued share capital of the Company. No Options may be granted to any eligible participant of the Share Option Scheme such that the total number of Shares issued and to be issued upon exercise of the Options granted and to be granted to that person in any 12-month period up to the date of the latest grant exceeds 1% of the Company's issued share capital for the time being.

An Option may be exercised in accordance with the terms of the Share Option Scheme at any time during a period as determined by the Board and not exceeding 10 years from the date of grant under the Share Option Scheme (the "Option Period"). After the expiration of the Option Period, no further Options shall be offered or granted but the provisions of the Share Option Scheme shall remain in full force and effect in all other respects. Options granted during the life of the Share Option Scheme shall continue to be exercisable in accordance with their terms of grant after the end of the ten-year period.

There is no general requirement on the minimum period for which an Option must be held or the performance targets which must be achieved before an Option can be exercised under the terms of the Share Option Scheme. Eligible participants of the Share Option Scheme are required to pay our Company HK\$1 upon acceptance of the grant within 28 days after the offer date.

The subscription price shall be determined by the Board in its absolute discretion but in any event shall not be less than the highest of:

- (i) the closing price of the Shares as stated in the daily quotations sheets issued by the Stock Exchange on the business day on which the Option is granted;
- the average closing price of the Shares as stated in the Stock Exchange's daily quotations sheets for the five (5) business days immediately preceding the date on which the Option is granted; and
- (iii) the nominal value of the Shares.

The Share Option Scheme is valid and effective for a period of 10 years from 8 July 2014, after which no further Options will be granted or offered.

During the year ended 30 June 2020, share options were granted by the Company under the Share Option Scheme to selected grantees to subscribe for an aggregate of 10,000,000 ordinary shares in the Company (30 June 2019: 8,000,000).

Option type	Date of grant	Exercisable period	Exercise price
2019 Type 1 Options	29 April 2019	30/04/2020 to 29/04/2029	HK\$1.440
	29 April 2019	30/04/2021 to 29/04/2029	HK\$1.440
2019 Type 2 Options	29 April 2019	30/04/2020 to 29/04/2029	HK\$1.440
	29 April 2019	30/04/2021 to 29/04/2029	HK\$1.440
2019 Type 3 Options	29 April 2019	30/04/2020 to 29/04/2029	HK\$1.440
	29 April 2019	30/04/2021 to 29/04/2029	HK\$1.440
	29 April 2019	30/04/2022 to 29/04/2029	HK\$1.440
2020 Type 1 Options	26 June 2020	27/06/2021 to 26/06/2030	HK\$0.994
	26 June 2020	27/06/2022 to 26/06/2030	HK\$0.994
2020 Type 2 Options	26 June 2020	27/06/2021 to 26/06/2030	HK\$0.994
options	26 June 2020	27/06/2022 to 26/06/2030	НК\$0.994
	26 June 2020	27/06/2023 to 26/06/2030	НК\$0.994

The following table discloses movements in the share options of the Company during the Year:

Category 1: Directors

Name of Director	Options type	Date of grant	Exercisable period	Number of Shares subject to the outstanding options as at 01.07.2019	Number of share options granted during the Year	Number of share options exercised during the Year	Number of share options cancelled during the Year	Number of share options forfeited during the Year	Number of Shares subject to the outstanding options as at 30.06.2020
Ms Hai Hiu Chu	2019 Type 1	29/04/2019	30/04/2020 to 29/04/2029	925,000	-	-	-	-	925,000
	2019 Type 1	29/04/2019	30/04/2021 to 29/04/2029	925,000	-	-	-	-	925,000
	2020 Type 1	26/06/2020	27/06/2021 to 26/06/2030	-	1,000,000	-	-	-	1,000,000
	2020 Type 1	26/06/2020	27/06/2022 to 26/06/2030	-	1,000,000	-	-	-	1,000,000
Dr Chan Kai Yue Jason	2020 Type 1	26/06/2020	27/06/2021 to 26/06/2030	-	150,000	-	-	-	150,000
	2020 Type 1	26/06/2020	27/06/2022 to 26/06/2030	-	150,000	-	-	-	150,000
Ms Chhoa Peck Lim Bella	2020 Type 1	26/06/2020	27/06/2021 to 26/06/2030	-	150,000	-	-	-	150,000
	2020 Type 1	26/06/2020	27/06/2022 to 26/06/2030	-	150,000	-	-	-	150,000
Mr Woo King Hang	2019 Type 3	29/04/2019	30/04/2020 to 29/04/2029	90,000	_	_	_	(90,000)	-
	2019 Type 3	29/04/2019	30/04/2021 to 29/04/2029	90,000	-	-	-	(90,000)	-
	2019 Type 3	29/04/2019	30/04/2022 to 29/04/2029	120,000	-	-	-	(120,000)	-
Dr Ko Wing Man	2020 Type 1	26/06/2020	27/06/2021 to 26/06/2030	_	150,000	_	_	(150,000)	-
, , , , , , , , , , , , , , , , , , ,	2020 Type 1	26/06/2020	27/06/2022 to 26/06/2030	-	150,000	-	-	(150,000)	-
Mr Wong Kon Man Jason	2019 Type 1	29/04/2019	30/04/2020 to 29/04/2029	125,000	_	-	-	_	125,000
2	2019 Type 1	29/04/2019	30/04/2021 to 29/04/2029	125,000	-	-	-	-	125,000
	2020 Type 1	26/06/2020	27/06/2021 to 26/06/2030	-	150,000	-	-	-	150,000
	2020 Type 1	26/06/2020	27/06/2022 to 26/06/2030		150,000	-	-	-	150,000
Total for Directors				2,400,000	3,200,000	-	-	(600,000)	5,000,000

Category 2: Employees

Employees	Options type	Date of grant	Exercisable period	Number of Shares subject to the outstanding options as at 01.07.2019	Number of share options granted during the Year	Number of share options exercised during the Year	Number of share options cancelled during the Year	Number of share options forfeited during the Year	Number of Shares subject to the outstanding options as at 30.06.2020
	options type	Dute of grant		01.07.2015				the real	50.00.2020
	2019 Type 2	29/04/2019	30/04/2020 to 29/04/2029	1,532,000	-	-	-	(188,000)	1,344,000
	2019 Type 2	29/04/2019	30/04/2021 to 29/04/2029	2,298,000	-	-	-	(282,000)	2,016,000
	2019 Type 3	29/04/2019	30/04/2020 to 29/04/2029	171,000	-	-	-	(96,000)	75,000
	2019 Type 3	29/04/2019	30/04/2021 to 29/04/2029	171,000	-	-	-	(96,000)	75,000
	2019 Type 3	29/04/2019	30/04/2022 to 29/04/2029	228,000	-	-	-	(128,000)	100,000
	2020 Type 1	26/06/2020	27/06/2021 to 26/06/2030	-	2,025,000	-	-	-	2,025,000
	2020 Type 1	26/06/2020	27/06/2022 to 26/06/2030	-	2,025,000	-	-	-	2,025,000
	2020 Type 2	26/06/2020	27/06/2021 to 26/06/2030	-	825,000	-	-	-	825,000
	2020 Type 2	26/06/2020	27/06/2022 to 26/06/2030	-	825,000	-	-	-	825,000
	2020 Type 2	26/06/2020	27/06/2023 to 26/06/2030		1,100,000	-	-	-	1,100,000
Total for Employees				4,400,000	6,800,000	-	-	(790,000)	10,410,000
All Categories				6,800,000	10,000,000	-	-	(1,390,000)	15,410,000

PERMITTED INDEMNITY PROVISION

The Company's articles of association provides that every Director is entitled to be indemnified out of the assets of the Company against all losses or liabilities which he/she may sustain or incur in or about the execution of duties of his/her office or otherwise in relation thereto provided that such indemnity shall not extend to any matter in respect of fraud or dishonesty which may attach to the Director.

The Company has taken out and maintained Directors' liability insurance throughout the Year, which provides appropriate cover for the Directors.

MAJOR CUSTOMERS AND SUPPLIERS

During the year ended 30 June 2020, the revenue attributable to our five largest clients accounted for less than 19% of the revenue for the Year. Costs payable to the five largest healthcare personnel placed by the Company also accounted for less than 10% of our total pay-out costs for the Year. During the Year, none of the Directors, their associates or any shareholder of the Company (which to the knowledge of the Directors owns more than 5% of the Company's issued share capital) had any interest in these clients or healthcare personnel of the Group.

CONNECTED TRANSACTIONS

None of the "Related Party Transactions" as set out in Note 34 to the consolidated financial statements for the Year constituted discloseable non-exempted connected transaction or non-exempted continuing connected transaction under the Listing Rules.

CORPORATE GOVERNANCE

Principal corporate governance practices as adopted by the Company are set out in the section headed "Corporate Governance Report" on pages 11 to 25.

MANAGEMENT CONTRACTS

No contracts concerning the management and administration of the whole or any substantial part of the business of the Company were entered into or existed during the Year.

COMPLIANCE WITH THE MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code for Securities Transactions by Directors of Listed Issuers (the "Model Code") as set out in Appendix 10 to the Rules Governing the Listing of Securities on the Stock Exchange (the "Listing Rules") as the code for securities transactions by Directors. The Directors, after specific enquiries made by the Company, confirmed their compliance with the required standards set out in the Model Code throughout the Year.

SUFFICIENCY OF PUBLIC FLOAT

Based on the information that is publicly available to the Company and within the knowledge of the Directors, up to the date of this annual report, there is sufficient public float of 25% of the Company's issued shares as required under the Listing Rules.

PRE-EMPTIVE RIGHTS

There is no provision for pre-emptive rights under the Company's articles of association and there was no restriction against such rights under the laws of the Cayman Islands, which would oblige the Company to offer new shares on a pro-rata basis to existing shareholders.

CHARITABLE DONATIONS

Charitable donations in cash made by the Group during the Year amounted to approximately HK\$70,000 (2019: HK\$66,000). Please also refer to the section headed "Environmental, Social and Governance Report" contained in this annual report for details of other sustainability initiatives and efforts made by our Group during the Year.

LEGAL COMPLIANCE

We have kept ourselves abreast with the development of laws, rules and regulations which have or may have a significant impact on, and have been abiding the laws, rules and regulations applicable to, the operation of our business.

We have devised and implemented policies and procedures within the business structure to ensure that the operations are being run in line with the applicable laws, rules and regulations, monitored its effectiveness through regular internal review, encouraged the employees and healthcare personnel registered with the Company to familiarise themselves with the applicable laws, rules and regulations so as to raise their awareness in this respect as well as for their own benefit.

During the Year, we had complied with and were not aware of any violation of the applicable laws, rules and regulations that have a significant impact on the business operation of the Group.

RELATIONSHIPS WITH EMPLOYEES, HEALTHCARE PERSONNEL AND CLIENTS

We are committed to maintaining, and consider that we have overall maintained good relations with the employees, the healthcare personnel registered with the Company and the clients, with a view to fostering mutual trust and better understanding towards each other, and on which the success and sustainability depend.

CLOSURE OF REGISTER OF MEMBERS

For the purpose of determining Shareholders' qualification to attend and vote at the AGM, the register of members of the Company will be closed from Tuesday, 3 November 2020 to Friday, 6 November 2020 (both days inclusive) during which period no transfer of shares may be effected. In order to qualify for attending and voting at the AGM, all transfer documents accompanied by the relevant share certificate(s) should be lodged for registration with Union Registrars Limited (the "Hong Kong Branch Share Registrar"), at Suites 3301–04, 33/F., Two Chinachem Exchange Square, 338 King's Road, North Point, Hong Kong by no later than 4:00 p.m. on Monday, 2 November 2020.

For the purpose of ascertaining Shareholders' entitlement to the recommended final dividend for the year ended 30 June 2020, the register of members of the Company will be closed from Friday, 13 November 2020 to Monday, 16 November 2020 (both days inclusive) during which period no transfer of the Shares may be effected. In order to qualify for the final dividend, all transfer documents accompanied by the relevant share certificate(s) should be lodged for registration with the Hong Kong Branch Share Registrar at the above address by no later than 4:00 p.m. on Thursday, 12 November 2020.

AUDITORS

The financial statements have been audited by PricewaterhouseCoopers who retire and, being eligible, offer themselves for re-appointment.

By order of the Board of Bamboos Health Care Holdings Limited Hai Hiu Chu Chairman

Hong Kong, 18 September 2020



羅兵咸永道

To the Shareholders of Bamboos Health Care Holdings Limited (incorporated in the Cayman Islands with limited liability)

OPINION

What we have audited

The consolidated financial statements of Bamboos Health Care Holdings Limited (the "Company") and its subsidiaries (the "Group") set out on pages 66 to 131, which comprise:

- the consolidated balance sheet as at 30 June 2020;
- the consolidated income statement for the year then ended;
- the consolidated statement of comprehensive income for the year then ended;
- the consolidated statement of changes in equity for the year then ended;
- the consolidated statement of cash flows for the year then ended; and
- the notes to the consolidated financial statements, which include a summary of significant accounting policies.

Our opinion

In our opinion, the consolidated financial statements give a true and fair view of the consolidated financial position of the Group as at 30 June 2020, and of its consolidated financial performance and its consolidated cash flows for the year then ended in accordance with Hong Kong Financial Reporting Standards ("HKFRSs") issued by the Hong Kong Institute of Certified Public Accountants ("HKICPA") and have been properly prepared in compliance with the disclosure requirements of the Hong Kong Companies Ordinance.

BASIS FOR OPINION

We conducted our audit in accordance with Hong Kong Standards on Auditing ("HKSAs") issued by the HKICPA. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We are independent of the Group in accordance with the HKICPA's Code of Ethics for Professional Accountants ("the Code"), and we have fulfilled our other ethical responsibilities in accordance with the Code.

PricewaterhouseCoopers, 22/F, Prince's Building, Central, Hong Kong T: +852 2289 8888, F: +852 2810 9888, www.pwchk.com

KEY AUDIT MATTERS

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key audit matter identified in our audit is related to revenue recognition of revenue from provision of healthcare staffing solution services.

Key Audit Matter

How our audit addressed the Key Audit Matter

Revenue recognition of revenue from provision of healthcare staffing solution services

Refer to Note 2.21, Note 4 and Note 6 to the consolidated financial statements.

For the year ended 30 June 2020, the Group recognised revenue from the provision of healthcare staffing solution services to private and institutional customers amounted to HK\$66,898,000.

The Group makes significant judgements in determining its role as an agent and presents all such revenue on a net basis, based on gross fee received or receivable from the customers, net of service fee paid or payable to the healthcare personnel. In making this determination, management has taken into account all the attributes in the existing service arrangements including, among others, the following factors:

- The terms of agreement with healthcare personnel which specify that there is no employment relationship between the Group and the healthcare personnel.
- The standard term sheet with customers which sets out certain material terms governing the relationship between the Group and the customers, including the term that the Group will perform a referral service for the customers based on their requested level of qualification of the healthcare personnel subject to the availability, which is not guaranteed by the Group, and the term that the Group does not directly participate in the performance of healthcare services and is not contractually responsible for the conduct, professional expertise or any liability in relation to the work of healthcare personnel so assigned to the customers.

We understood, evaluated and validated the key controls over the revenue recognition in respect of initiation of transactions and referral of healthcare personnel, the basis, calculation and timing of the recognition.

We tested, on a sample basis, the agreements the Group signed with the healthcare personnel and service fee reports issued by the Group to the healthcare personnel. We also checked the relevant terms in the agreements to validate management's explanation that the healthcare personnel have no employment relationship with the Group, and the Group is not required to pay any service fee to the healthcare personnel in case of customer default.

We tested, on a sample basis, the standard term sheet and invoices issued by the Group to the customers. We also checked the standard term sheet stating that (i) the Group will perform a referral service for the customers based on their requested level of qualification of the healthcare personnel subject to the availability, which is not guaranteed by the Group; and (ii) the Group does not directly participate in the performance of healthcare services and is not contractually responsible for the conduct, professional expertise or any liability in relation to the work of healthcare personnel so assigned to the customers.

Key Audit Matter	How our audit addressed the Key Audit Matter
We focus on revenue recognition due to the high volume of transactions, significance of the balance to the consolidated financial statements, and the significant management judgements involved in determining its role as an agent and thus resultant presentation of revenue on a net basis.	We also tested, on a sample basis, the accuracy of revenue transactions by obtaining the agency income schedule, checking the mathematic accuracy and recalculating the revenue from provision of healthcare staffing solution services.
	We also inquired and assessed management's assessment of the determination of revenue recognition on a net basis in accordance with the applicable accounting framework.
	Based on the procedures performed above, we found the revenue transactions tested including management's judgements made in revenue transactions were supported by available evidence.

OTHER INFORMATION

The directors of the Company are responsible for the other information. The other information comprises all of the information included in the annual report other than the consolidated financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

RESPONSIBILITIES OF DIRECTORS AND THOSE CHARGED WITH GOVERNANCE FOR THE CONSOLIDATED FINANCIAL STATEMENTS

The directors of the Company are responsible for the preparation of the consolidated financial statements that give a true and fair view in accordance with HKFRSs issued by the HKICPA and the disclosure requirements of the Hong Kong Companies Ordinance, and for such internal control as the directors determine is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, the directors are responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the Group or to cease operations, or have no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Group's financial reporting process.

AUDITOR'S RESPONSIBILITIES FOR THE AUDIT OF THE CONSOLIDATED FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. We report our opinion solely to you, as a body, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with HKSAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with HKSAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors.
- Conclude on the appropriateness of the directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partner on the audit resulting in this independent auditor's report is Ho Chun Yu.

PricewaterhouseCoopers *Certified Public Accountants*

Hong Kong, 18 September 2020

Consolidated Income Statement

For the year ended 30 June 2020

		2020	2019
	Note	HK\$'000	HK\$'000
Revenue from contracts with customers	6	72,318	78,464
Other income	7	5,237	3,299
Other gains, net	8	611	1,094
Employee benefit expenses	10	(24,051)	(18,007)
Operating lease rentals		(1,758)	(5,418)
Depreciation of property, plant and equipment	16	(2,234)	(875)
Depreciation of right-of-use assets	17	(3,570)	_
Other expenses	9	(10,413)	(10,389)
Operating profit		36,140	48,168
Finance income	12	1,048	1,087
Finance costs	12	(326)	_
Share of losses of a joint venture	18	(686)	(1,207)
Share of losses of an associate			(930)
Profit before income tax		36,176	47,118
Income tax expense	13	(5,486)	(8,198)
Profit for the year		30,690	38,920
Profit for the year attributable to:		20.004	20.020
Equity holders of the Company		30,691	38,920
Non-controlling interests		(1)	
		30,690	38,920
Earnings per share attributable to equity holders of the Company for the year (expressed in HK cents per share)			
Basic and diluted	14	HK7.67 cents	HK9.73 cents

The above consolidated income statement should be read in conjunction with accompanying notes.

Consolidated Statement of Comprehensive Income

For the year ended 30 June 2020

	2020 HK\$′000	2019 HK\$'000
Profit for the year	30,690	38,920
Other comprehensive income		
Item that may be reclassified to profit or loss Currency translation differences	62	(5)
Total comprehensive income for the year	30,752	38,915
Total comprehensive income for the year attributable to: Equity holders of the Company Non-controlling interests	30,753 (1)	38,915
	30,752	38,915

The above consolidated statement of comprehensive income should be read in conjunction with the accompanying notes.

Consolidated Balance Sheet

As at 30 June 2020

	Note	2020 HK\$'000	2019 HK\$'000
ASSETS			
Non-current assets			
Property, plant and equipment	16	4,870	4,897
Right-of-use assets	17	5,096	_
Investment in a joint venture	18	412	1,033
Prepayments and deposits	23	11,444	7,399
Financial assets at fair value through profit or loss	19	28,449	-
Deferred income tax assets	31	203	
		50,474	13,329
Current assets			
Inventories	22	930	947
Trade receivables	21	24,240	41,426
Prepayments, deposits and other receivables	23	4,353	5,714
Amounts due from related companies	24	249	892
Cash and cash equivalents	25	101,633	118,703
		131,405	167,682
Total assets	_	181,879	181,011

The above consolidated balance sheet should be read in conjunction with the accompanying notes.

Consolidated Balance Sheet

As at 30 June 2020

	Note	2020 HK\$'000	2019 HK\$'000
EQUITY AND LIABILITIES			
Capital and reserves attributable to equity holders of the Company			
Share capital	26	4,000	4,000
Share premium	26	39,123	39,123
Reserves	27	110,148	106,858
		153,271	149,981
Non-controlling interests	_	2	
Total equity	_	153,273	149,981
Non-current liabilities			
Lease liabilities	17	2,740	_
Deferred income tax liabilities	31	_	192
		2,740	192
Current liabilities			
Trade payables	29	12,750	16,260
Accruals and other payables	30	4,450	4,666
Lease liabilities	17	3,019	_
Tax payable	_	5,647	9,912
		25,866	30,838
Total liabilities	_	28,606	31,030
Total equity and liabilities	_	181,879	181,011

The consolidated financial statements on pages 66 to 131 were approved by the Board of Directors on 18 September 2020 and were signed on its behalf.

Hai Hiu Chu

Director

The above consolidated balance sheet should be read in conjunction with the accompanying notes.

Consolidated Statement of Changes in Equity

For the year ended 30 June 2020

_	Attributable to equity holders of the Company							
_	Share capital (Note 26) HK\$'000	Share premium (Note 26) HK\$'000	Share-based compensation reserve (Note 28) HK\$'000	Translation reserve HK\$'000	Retained earnings HK\$'000	Sub-total HK\$'000	Non- controlling interests HK\$'000	Total equity HK\$'000
At 1 July 2018	4,000	39,123	-	2	77,392	120,517	-	120,517
Profit for the year Currency translation	-	-	-	-	38,920	38,920	-	38,920
differences	-	-	-	(5)		(5)		(5)
Total comprehensive income	-	-	-	(5)	38,920	38,915	-	38,915
Transaction with owners: 2018 final dividend								
(Note 15)	-	-	-	-	(10,000)	(10,000)	-	(10,000)
Employee share scheme	-	-	549	-	-	549	-	549
-	-	_	549	-	(10,000)	(9,451)	-	(9,451)
At 30 June 2019	4,000	39,123	549	(3)	106,312	149,981	-	149,981
At 1 July 2019	4,000	39,123	549	(3)	106,312	149,981	-	149,981
Profit for the year Currency translation	-	-	-	-	30,691	30,691	(1)	30,690
differences	-	-	-	62	-	62	-	62
Total comprehensive income	-	-	-	62	30,691	30,753	(1)	30,752
Transaction with owners: 2019 final dividend								
(Note 15) 2020 interim dividend	-	-	-	-	(20,000)	(20,000)	-	(20,000)
(Note 15) Capital injection from	-	-	-	-	(10,000)	(10,000)	-	(10,000)
non-controlling interests	-	-	-	-	-	-	3	3
Employee share scheme	-	-	2,537	-	-	2,537	-	2,537
-	-	-	2,537	-	(30,000)	(27,463)	3	(27,460)
At 30 June 2020	4,000	39,123	3,086	59	107,003	153,271	2	153,273
-								

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

Consolidated Statement of Cash Flows

For the year ended 30 June 2020

	Note _	2020 HK\$'000	2019 HK\$'000
Cash flows from operating activities			
Cash generated from operations	35(a)	54,943	40,326
Interest paid		(326)	_
Income tax paid	_	(10,146)	(8,359)
Net cash generated from operating activities		44,471	31,967
Cash flows from investing activities			
Purchase of property, plant and equipment	16	(2,620)	(214)
Payment for acquisition of financial assets at FVTPL		(38,062)	_
Proceeds from disposals of financial assets at FVTPL		10,964	_
Payment for acquisition of subsidiaries, net of cash acquired		-	(1,148)
Proceeds from disposals of property, plant and equipment		-	205
Interest received	_	1,048	1,087
Net cash used in investing activities		(28,670)	(70)
Cash flows from financing activities			
Dividends paid	15	(30,000)	(10,000)
Capital injection from non-controlling interest		3	_
Principal elements of lease payments	_	(2,871)	
		<i>(</i>)	<i>(</i>
Net cash used in financing activities		(32,868)	(10,000)
Net (decrease)/increase in cash and cash equivalents		(17,067)	21,897
Cash and cash equivalents at the beginning of the year	25	118,703	96,806
Effect of foreign exchange rate changes on cash and cash equivalents	_	(3)	
Cash and cash equivalents at the end of the year	25	101,633	118,703

The above consolidated statement of cash flows should be read in conjunction with the accompanying notes.

1 GENERAL INFORMATION

Bamboos Health Care Holdings Limited (the "Company") and its subsidiaries (together, the "Group") are principally engaged in the provision of healthcare staffing solution services in Hong Kong. The Group is also engaged in provision of outreach case assessment related services and operation of aesthetic clinic.

The Company was incorporated in the Cayman Islands on 23 November 2012 as an exempted company with limited liability under the Companies Law, Cap. 22 (Law 3 of 1961, as consolidated and revised) of the Cayman Islands. The address of its registered office is PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands and its principal place of business is Room 204, 2/F, Wing On Plaza, 62 Mody Road, Tsim Sha Tsui, Kowloon, Hong Kong.

The Company is listed on the Main Board of The Stock Exchange of Hong Kong Limited (the "Stock Exchange").

These consolidated financial statements are presented in thousands of units of Hong Kong dollars ("HK\$'000"), unless otherwise stated.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The principal accounting policies applied in the preparation of these consolidated financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

2.1 Basis of preparation

The consolidated financial statements have been prepared in accordance with Hong Kong Financial Reporting Standards ("HKFRSs") and requirements of the Hong Kong Companies Ordinance Cap. 622. The consolidated financial statements have been prepared under the historical cost convention, except for the financial assets at fair value through profit or loss which are carried at fair value.

The preparation of consolidated financial statements in conformity with HKFRSs requires the use of certain critical accounting estimates. It also requires management to exercise its judgement in the process of applying the Group's accounting policies. The areas involving a higher degree of judgement or complexity, or areas where assumptions and estimates are significant to the consolidated financial statements are disclosed in Note 4.

(a) New standard, amendments to standards and interpretation adopted by the Group

The Group has applied the following new standard, amendments to standards and interpretation for the first time for their annual reporting period commencing 1 July 2019:

Annual Improvements Project	Annual Improvements 2015–2017 Cycle
(Amendment)	
HKAS 19 (Amendment)	Plan Amendment, Curtailment or Settlement
HKAS 28 (Amendment)	Long-term Interests in Associates and Joint Ventures
HKFRS 9 (Amendment)	Prepayment Features with Negative Compensation
HKFRS 16	Leases
HKFRS 16 (Amendment)	COVID-19-Related Rent Concessions
HK(IFRIC)-Int 23	Uncertainty over Income Tax Treatments

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.1 Basis of preparation (Continued)

(a) New standard, amendments to standards and interpretation adopted by the Group (Continued)

The Group had to change its accounting policies as a result of adopting HKFRS 16. The Group elected to adopt the new rules retrospectively but recognised the cumulative effect of initially applying the new standard on 1 July 2019. This is disclosed in Note 2.2. Other amendments to standards and interpretation listed above did not have any impact on the amounts recognised in prior periods and are not expected to significantly affect the current or future periods.

(b) New standard, amendments to standards and conceptual framework not yet adopted by the Group

The new standard, amendments to standards and conceptual framework relevant to the Group which have been issued, but not effective for the financial year beginning 1 July 2019 and have not been early adopted by the Group. These new standard, amendments to standards and conceptual framework are not expected to have a material impact on the entity in the current or future reporting periods and on foreseeable future transactions:

		Effective for accounting year beginning on or after
	- 6	
HKAS 1 and HKAS 8 (Amendments)	Definition of Material	1 January 2020
HKAS 39, HKFRS 7 and HKFRS 9 (Amendments)	Interest Rate Benchmark Reform	1 January 2020
HKFRS 3 (Amendments)	Definition of Business	1 January 2020
Conceptual Framework for Financial Reporting 2018	Revised Conceptual Framework for Financial Reporting	1 January 2020
HKFRS 9, HKAS 39 and HKFRS 7 (Amendments)	Hedge Accounting	1 January 2020
HKAS 1 (Amendments)	Classification of Liabilities as Current or Non-Current	1 January 2022
HKAS 16 (Amendments)	Proceeds Before Intended Use	1 January 2022
HKFRS 17	Insurance Contracts	1 January 2023
HKFRS 10 and HKAS 28 (Amendments)	Sale or Contribution of Assets Between an Investor and its Associate or Joint Venture	To be announced

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.2 Changes in accounting policies

This note explains the impact of the adoption of HKFRS 16 Leases on the Group's consolidated financial statements.

As indicated in Note 2.1(a) above, the Group has adopted HKFRS 16 Leases retrospectively from 1 July 2019, but has not restated comparatives for the 2019 reporting period, as permitted under the specific transition provisions in the standard. The reclassifications and the adjustments arising from the new leasing rules are therefore recognised in the opening consolidated balance sheet on 1 July 2019. The new accounting policies are disclosed in Note 2.23.

On adoption of HKFRS 16, the Group recognised lease liabilities in relation to leases which had previously been classified as 'operating leases' under the principles of HKAS 17 Leases. These liabilities were measured at the present value of the remaining lease payments, discounted using the lessee's incremental borrowing rate as of 1 July 2019. The weighted average lessee's incremental borrowing rate applied to the lease liabilities on 1 July 2019 was 5.17%.

(i) Practical expedients applied

In applying HKFRS 16 for the first time, the Group has used the following practical expedients permitted by the standard:

- applying a single discount rate to a portfolio of leases with reasonably similar characteristics; and
- accounting for operating leases with a remaining lease term of less than 12 months as at 1 July 2019 as short-term leases.

The Group has also elected not to reassess whether a contract is, or contains a lease at the date of initial application.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.2 Changes in accounting policies (Continued)

(ii) Measurement of lease liabilities

The reconciliation between the operating lease commitments as disclosed as at 30 June 2019 and the lease liabilities recognised in the consolidated balance sheet as at 1 July 2019 (date of initial application of HKFRS 16) is as follows:

	HK\$'000
Operating lease commitments disclosed as at 30 June 2019	5,953
Discounted using the lessee's incremental borrowing rate at the date of initial application Less: short-term leases not recognised as a liability	5,320 (2,594)
Lease liabilities recognised as at 1 July 2019	2,726
Of which are: Current lease liabilities Non-current lease liabilities	1,843 883
	2,726

(iii) Measurement of right-of-use assets

The associated right-of-use assets were measured at the amount equal to the lease liability, adjusted by the amount of any prepaid or accrued lease payments relating to that lease recognised in the consolidated balance sheet as at 30 June 2019.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.2 Changes in accounting policies (Continued)

(iv) Adjustments recognised in the consolidated balance sheet as at 1 July 2019

As a lessee, the Group's leases are mainly rentals of offices. The change in accounting policies affected the following items in the consolidated balance sheet as at 1 July 2019:

Consolidated balance sheet (extracted)	30 June 2019 (As previously stated) HK\$'000	Adjustments on adoption of HKFRS 16 HK\$'000	1 July 2019 (Restated) HK\$'000
Non-current assets Property, plant and equipment Right-of-use assets	4,897 _	(156) 2,762	4,741 2,762
Non-current liabilities Lease liabilities	-	883	883
Current liabilities Accruals and other payables Lease liabilities	4,666 –	(120) 1,843	4,546 1,843

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.3 Principles of consolidation and equity accounting

2.3.1 Subsidiaries

Subsidiaries are all entities (including structured entities) over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date that control ceases.

Intra-group transactions, balances and unrealised gains on transactions between group companies are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group.

Non-controlling interests in the results and equity of subsidiaries are shown separately in the consolidated income statement, statement of comprehensive income, statement of changes in equity and balance sheet respectively.

2.3.2 An associate

An associate is the entity over which the Group has significant influence but not control or joint control. This is generally the case where the Group holds between 20% and 50% of the voting rights. Investment in an associate is accounted for using the equity method of accounting (see Note 2.3.4 below), after initially being recognised at cost.

2.3.3 A joint venture

Investment in a joint venture is accounted for using the equity method (see Note 2.3.4 below), after initially being recognised at cost in the consolidated balance sheet.

2.3.4 Equity accounting

Under the equity method of accounting, the investments are initially recognised at cost and adjusted thereafter to recognise the Group's share of the profits or losses of the investee in profit or loss, and the Group's share of movements in other comprehensive income ("OCI") of the investee in OCI. Dividends received or receivable from associate and joint venture are recognised as a reduction in the carrying amount of the investments.

When the Group's share of losses in an equity-accounted investment equals or exceeds its interest in the entity, including any other unsecured long-term receivables, the Group does not recognise further losses, unless it has incurred obligations or made payments on behalf of the other entity.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.3 Principles of consolidation and equity accounting (Continued)

2.3.4 Equity accounting (Continued)

Unrealised gains on transactions between the Group and its associates and joint ventures are eliminated to the extent of the Group's interest in these entities. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Accounting policies of equity accounted investees have been changed where necessary to ensure consistency with the policies adopted by the Group.

The carrying amount of equity-accounted investments is tested for impairment in accordance with the policy described in Note 2.9.

2.4 Business combinations

The acquisition method of accounting is used to account for all business combinations, regardless of whether equity instruments or other assets are acquired. The consideration transferred for the acquisition of a subsidiary comprises the:

- fair values of the assets transferred;
- liabilities incurred to the former owners of the acquired business;
- equity interests issued by the group;
- fair value of any asset or liability resulting from a contingent consideration arrangement; and
- fair value of any pre-existing equity interest in the subsidiary.

Acquisition-related costs are expensed as incurred.

The excess of the:

- consideration transferred;
- amount of any non-controlling interest in the acquired entity; and
- acquisition-date fair value of any previous equity interest in the acquired entity.

over the fair value of the net identifiable assets acquired is recorded as goodwill. If those amounts are less than the fair value of the net identifiable assets of the business acquired, the difference is recognised directly in profit or loss as a bargain purchase.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.4 Business combinations (Continued)

Contingent consideration is classified either as equity or a financial liability. Amounts classified as a financial liability are subsequently remeasured to fair value with changes in fair value recognized in profit or loss.

If the business combination is achieved in stages, the acquisition date carrying value of the acquirer's previously held equity interest in the acquiree is remeasured to fair value at the acquisition date. Any gains or losses arising from such remeasurement are recognized in profit or loss.

2.5 Separate financial statements

Investments in subsidiaries are accounted for at cost less impairment. Cost also includes directly attributable costs of investment. The results of subsidiaries are accounted for by the Company on the basis of dividend received and receivable.

Impairment testing of the investments in subsidiaries is required upon receiving a dividend from these investments if the dividend exceeds the total comprehensive income of the subsidiary in the period the dividend is declared or if the carrying amount of the investment in the separate financial statements exceeds the carrying amount in the consolidated financial statements of the investee's net assets including goodwill.

2.6 Segment reporting

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision-maker. The chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the executive directors of the Company who make strategic decisions.

2.7 Foreign currency translation

(i) Functional and presentation currency

Items included in the financial statements of each of the Group's entities are measured using the currency of the primary economic environment in which the Company operates (the "functional currency"). The consolidated financial statements are presented in Hong Kong dollars ("HK\$" or "HKD"), which is the Company's functional and the Group's presentation currency.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.7 Foreign currency translation (Continued)

(ii) Transactions and balances

Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates are generally recognised in profit or loss.

Foreign exchange gains and losses that relate to borrowings are presented in the consolidated income statement, within finance costs. All other foreign exchange gains and losses are presented in the consolidated income statement on a net basis within other gains, net.

(iii) Group companies

The results and financial position of foreign operations (none of which has the currency of a hyperinflationary economy) that have a functional currency different from the presentation currency are translated into the presentation currency as follows:

- assets and liabilities for each balance sheet presented are translated at the closing rate at the date of that balance sheet;
- income and expenses for each income statement and statement of comprehensive income are translated at average exchange rates (unless this is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated at the dates of the transactions); and
- all resulting exchange differences are recognised in OCI.

On consolidation, exchange differences arising from the translation of any net investment in foreign entities, and of borrowings and other financial instruments designated as hedges of such investments, are recognised in OCI. When a foreign operation is sold or any borrowings forming part of the net investment are repaid, the associated exchange differences are reclassified to profit or loss, as part of the gain or loss on sale.

Goodwill and fair value adjustments arising on the acquisition of a foreign operation are treated as assets and liabilities of the foreign operation and translated at the closing rate.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.7 Foreign currency translation (Continued)

(iv) Disposal of foreign operation and partial disposal

On the disposal of a foreign operation (that is, a disposal of the Group's entire interest in a foreign operation, or a disposal involving loss of control over a subsidiary that includes a foreign operation, a disposal involving loss of joint control over a joint venture that includes a foreign operation, or a disposal involving loss of significant influence over an associate that includes a foreign operation), all of the currency translation differences accumulated in equity in respect of that operation attributable to the equity holders of the company are reclassified to profit or loss.

In the case of a partial disposal that does not result in the Group losing control over a subsidiary that includes a foreign operation, the proportionate share of accumulated currency translation differences are re-attributed to non-controlling interests and are not recognised in profit or loss. For all other partial disposals (that is, reductions in the Group's ownership interest in associates or joint ventures that do not result in the Group losing significant influence or joint control), the proportionate share of the accumulated exchange difference is reclassified to profit or loss.

2.8 Property, plant and equipment

Property, plant and equipment are stated at historical cost less accumulated depreciation and accumulated impairment losses, if any. Historical cost includes expenditure that is directly attributable to the acquisitions of the items.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognised when replaced. All other repairs and maintenance are charged to profit or loss during the period in which they are incurred.

Depreciation is calculated using the straight-line method to allocate cost net of their residual values, over their estimated useful lives or, in the case of leasehold improvement, the shorter lease term, as follows:

Leasehold improvements	33%
Furniture and fixtures	20%
Operating equipment and machinery	10%-20%
Computer equipment	20%
Motor vehicles	20%

The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period. An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount. These are included in profit or loss.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.9 Impairment of non-financial assets

Assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs of disposal and value in use. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows which are largely independent of the cash inflows from other assets or groups of assets ("cash-generating units"). Non-financial assets other than goodwill that suffered an impairment are reviewed for possible reversal of the impairment at each reporting period.

2.10 Financial assets

(a) Classification

The Group classifies its financial assets in the following measurement categories:

- those to be measured subsequently at fair value through profit or loss ("FVTPL"); and
- those to be measured at amortised cost.

The classification depends on the entity's business model for managing the financial assets and the contractual terms of the cash flows.

For assets measured at fair value, gains and losses will either be recorded in profit or loss or OCI. For investments in equity instruments that are not held for trading, this will depend on whether the Group has made an irrevocable election at the time of initial recognition to account for the equity investment at fair value through other comprehensive income ("FVOCI").

The Group reclassifies debt investments when and only when its business model for managing those assets changes.

(b) Recognition and derecognition

Regular way purchases and sales of financial assets are recognised on trade-date, the date on which the Group commits to purchase or sell the asset. Financial assets are derecognised when the rights to receive cash flows from the financial assets have expired or have been transferred and the Group has transferred substantially all the risks and rewards of ownership.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.10 Financial assets (Continued)

(c) Measurement

At initial recognition, the Group measures a financial asset at its fair value plus, in the case of a financial asset not at FVTPL, transaction costs that are directly attributable to the acquisition of the financial asset. Transaction costs of financial assets carried at FVTPL are expensed in the profit or loss.

Debt instruments

Subsequent measurement of debt instruments depends on the Group's business model for managing the asset and the cash flow characteristics of the asset. The Group classifies its debt instruments into following category:

(i) Amortised cost

Assets that are held for collection of contractual cash flows where those cash flows represent solely payments of principal and interest are measured at amortized cost. Interest income from these financial assets is included in finance income using the effective interest rate method. Any gain or loss arising on derecognition is recognized directly in profit or loss and presented in other gains, net together with foreign exchange gains and losses. Impairment losses are presented as separate line item in the consolidated income statement.

(ii) FVTPL

Assets that do not meet the criteria for amortised cost or FVOCI are measured at FVTPL. A gain or loss on a debt investment that is subsequently measured at FVTPL is recognised in profit or loss and presented net within other gains, net in the period in which it arises.

Equity instruments

The Group subsequently measures all equity investments at fair value. Dividends from such investments continue to be recognised in profit or loss as other income when the Group's right to receive payments is established.

Changes in the fair value of financial assets at FVTPL are recognised in other gains, net in the consolidated income statement as applicable.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.10 Financial assets (Continued)

(d) Impairment

The Group assesses on a forward looking basis the expected credit losses associated with its assets carried at amortised cost. The impairment methodology applied depends on whether there has been a significant increase in credit risk.

For trade receivables, the Group applies the simplified approach permitted by HKFRS 9, which requires expected lifetime losses to be recognized from initial recognition of the receivables. See Note 2.13 for further details.

2.11 Inventories

Inventories are stated at the lower of cost and net realisable value. Costs are assigned to individual items of inventory on the basis of weighted average cost. Costs of purchased inventory are determined after deducting rebates and discounts. Net realisable value is the estimated selling price in the ordinary course of business less the estimated costs necessary to make the sale.

2.12 Offsetting financial instruments

Financial assets and liabilities are offset and the net amount is reported in the consolidated balance sheet where the Group currently has a legally enforceable right to offset the recognised amounts, and there is an intention to settle on a net basis or realise the asset and settle the liability simultaneously. The Group has also entered into arrangements that do not meet the criteria for offsetting but still allow for the related amounts to be set off in certain circumstances, such as bankruptcy or the termination of a contract.

2.13 Trade receivables

Trade receivables are amounts due from customers for services performed in the ordinary course of business. If collection of trade and other receivables is expected in one year or less (or in the normal operating cycle of the business if longer), they are classified as current assets. If not, they are presented as non-current assets.

Trade receivables are recognised initially at the amount of consideration that is unconditional unless they contain significant financing components, when they are recognised at fair value. The group holds the trade receivables with the objective to collect the contractual cash flows and therefore measures them subsequently at amortised cost using the effective interest method. See Note 3.1(b) for a description of the Group's impairment policies.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.14 Cash and cash equivalents

For the purpose of presentation in the consolidated statement of cash flows, cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short term, highly liquid investments with original maturities of three months or less that are really convertible into known amounts of cash and which are subject to insignificant risk of changes in value.

2.15 Share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds.

2.16 Trade and other payables

These amounts represent liabilities for goods and services provided to the Group prior to the end of financial year which are unpaid. Trade and other payables are presented as current liabilities unless payment is not due within 12 months after the reporting period. They are recognised initially at their fair value and subsequently measured at amortised cost using the effective interest method.

2.17 Current and deferred income tax

The income tax expense or credit for the period is the tax payable on the current period's taxable income based on the applicable income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses.

(a) Current income tax

The current income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the end of the reporting period in the countries where the company and its subsidiaries and associates operate and generate taxable income. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.17 Current and deferred income tax (Continued)

(b) Deferred income tax

Deferred income tax is provided in full, using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the consolidated financial statements. However, deferred tax liabilities are not recognised if they arise from the initial recognition of goodwill. Deferred income tax is also not accounted for if it arises from initial recognition of an asset or liability in a transaction other than a business combination that at the time of the transaction affects neither accounting nor taxable profit or loss. Deferred income tax is determined using tax rates (and laws) that have been enacted or substantially enacted by the end of the reporting period and are expected to apply when the related deferred income tax asset is realised or the deferred income tax liability is settled.

Deferred tax assets are recognised only if it is probable that future taxable amounts will be available to utilise those temporary differences and losses.

Deferred tax liabilities and assets are not recognised for temporary differences between the carrying amount and tax bases of investments in foreign operations where the company is able to control the timing of the reversal of the temporary differences and it is probable that the differences will not reverse in the foreseeable future.

Deferred tax assets and liabilities are offset where there is a legally enforceable right to offset current tax assets and liabilities and where the deferred tax balances relate to the same taxation authority. Current tax assets and tax liabilities are offset where the entity has a legally enforceable right to offset and intends either to settle on a net basis, or to realise the asset and settle the liability simultaneously.

Current and deferred tax is recognised in profit or loss, except to the extent that it relates to items recognised in OCI or directly in equity. In this case, the tax is also recognised in OCI or directly in equity, respectively.

2.18 Employee benefits

(a) Pension obligations

The Group operates a number of defined contribution plans. Under defined contribution plans, the Group pays contributions to publicly or privately administered pension insurance plans on a mandatory, contractual or voluntary basis. The Group has no further payment obligations once the contributions have been paid. The contributions are recognised as employee benefit expense when they are due. Prepaid contributions are recognised as an asset to the extent that a cash refund or a reduction in the future payments is available.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.18 Employee benefits (Continued)

(b) Bonus plan

The expected cost of bonus payments is recognised as a liability when the Group has a present legal or constructive obligation as a result of services rendered by employees and a reliable estimate of the obligation can be made. Liabilities of bonus plan are expected to be settled within twelve months and are measured at the amounts expected to be paid when they are settled.

2.19 Share-based payments

Share-based compensation benefits are provided to directors and employees via the employee option plan scheme. Information relating to these schemes is set out in Note 28.

The fair value of options granted under the employee option plan is recognised as an employee benefits expense with a corresponding increase in equity.

The total amount to be expensed is determined by reference to the fair value of the options granted:

- including any market performance conditions (for example, an entity's share price);
- excluding the impact of any service and non-market performance vesting conditions (for example, profitability, sales growth targets and remaining an employee of the entity over a specified time period); and
- including the impact of any non-vesting conditions (for example, the requirement for employees to save or hold shares for a specified period of time).

The total expense is recognised over the vesting period, which is the period over which all of the specified vesting conditions are to be satisfied. At the end of each period, the entity revises its estimates of the number of options that are expected to vest based on the non-market vesting and service conditions. It recognises the impact of the revision to original estimates, if any, in profit or loss, with a corresponding adjustment to equity.

When the options are exercised, the Company issues new shares. The proceeds received net of any directly attributable transaction costs are credited to equity.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.20 Provisions

Provisions are recognised when the Group has a present legal or constructive obligation as a result of past events, it is probable that an outflow of resources will be required to settle the obligation and the amount can be reliably estimated. Provisions are not recognised for future operating losses.

Where there are a number of similar obligations, the likelihood that an outflow will be required in settlement is determined by considering the class of obligations as a whole. A provision is recognised even if the likelihood of an outflow with respect to any one item included in the same class of obligations may be small.

Provisions are measured at the present value of management's best estimate of the expenditure required to settle the present obligation at the end of the reporting period. The discount rate used to determine the present value is a pre-tax rate that reflects current market assessments of the time value of money and the risks specific to the liability. The increase in the provision due to the passage of time is recognised as interest expense.

2.21 Revenue recognition

Revenue is measured at the fair value of consideration received or receivable for the sale of goods or services rendered in the ordinary course of the Group's activities. Revenue is shown net of discounts and after eliminating sales within the Group.

The Group recognizes revenue when the control of goods or services is transferred to a customer. Depending on the terms of the contract and the laws that apply to the contract, control of the goods and services may be transferred over time or at a point in time and when specific criteria have been met for each of the Group's activities as described below. The Group bases its estimates of return on historical results, taking into consideration the type of customers, the type of transactions and the specifies of each arrangement.

- (a) Revenue from the provision of healthcare staffing solution services is recognised at point in time when the relevant services have been performed by the healthcare personnel as referred by the Group in accordance with services requested by the respective healthcare service demanders.
- (b) Revenue from outreach services is recognised over the time because the customer simultaneously receives and consumes the benefits provided by the Group.
- (c) Revenue from operation of aesthetic clinic is recognised at point in time when the services are rendered.
- (d) Activity income is recognised at point in time when the services are rendered.
- (e) Advertising income is recognised at point in time when the relevant advertisements have been published on a healthcare-related magazine which is issued by the Group for free distributions.
- (f) Sales of goods are recognised at point in time when a group entity sells a product to the customer. Retail sales are usually in cash or by credit card.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.22 Earnings per share

(i) Basic earnings per share

Basic earnings per share is calculated by dividing:

- the profit attributable to the equity holders of the Company, excluding any costs of servicing equity other than ordinary shares; and
- by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the year and excluding treasury shares.

(ii) Diluted earnings per share

Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account:

- the after-income tax effect of interest and other financing costs associated with dilutive potential ordinary shares; and
- the weighted average number of additional ordinary shares that would have been outstanding assuming the conversion of all dilutive potential ordinary shares.

2.23 Leases

As explained in Note 2.2 above, the Group has changed its accounting policy for leases where the Group is the lessee. The new policy is described below and the impact of the change in Note 2.2.

Until 30 June 2019, leases in which a significant portion of the risks and rewards of ownership were not transformed to the Group as lessee were classified as operating leases (Note 33). Payments made under operating leases (net of any incentives received from the lessor) are charged to the profit or loss on a straight-line basis over the period of the lease.

From 1 July 2019, leases are recognised as a right-of-use asset and a corresponding liability at the date at which the leased asset is available for use by the Group.

Contracts may contain both lease and non-lease components. The Group allocates the consideration in the contract to the lease and non-lease components based on their relative stand-alone prices.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.23 Leases (Continued)

Assets and liabilities arising from a lease are initially measured on a present value basis. Lease liabilities include the net present value of the following lease payments:

- fixed payments (including in-substance fixed payments), less any lease incentives receivable;
- variable lease payment that are based on an index or a rate, initially measured using the index or rate as at the commencement date;
- amounts expected to be payable by the lessee under residual value guarantees;
- the exercise price of a purchase option if the lessee is reasonably certain to exercise that option; and
- payments of penalties for terminating the lease, if the lease term reflects the lessee exercising that option.

Lease payments to be made under reasonably certain extension options are also included in the measurement of the liability.

The lease payments are discounted using the interest rate implicit in the lease. If that rate cannot be readily determined, which is generally the case for leases in the Group, the lessee's incremental borrowing rate is used, being the rate that the individual lessee would have to pay to borrow the funds necessary to obtain an asset of similar value to the right-of-use asset in a similar economic environment with similar terms, security and conditions.

To determine the incremental borrowing rate, the Group:

- where possible, uses recent third-party financing received by the individual lessee as a starting point, adjusted to reflect changes in financing conditions since third party financing was received;
- uses a build-up approach that starts with a risk-free interest rate adjusted for credit risk for leases held by the Group, which does not have recent third party financing; and
- makes adjustments specific to the lease, eg term, country, currency and security.

Lease payments are allocated between principal and finance cost. The finance cost is charged to profit or loss over the lease period so as to produce a constant periodic rate of interest on the remaining balance of the liability for each period.

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.23 Leases (Continued)

Right-of-use assets are measured at cost comprising the following:

- the amount of the initial measurement of lease liability;
- any lease payments made at or before the commencement date less any lease incentives received;
- any initial direct costs; and
- restoration costs.

Right-of-use assets are generally depreciated over the shorter of the asset's useful life and the lease term on a straight-line basis. If the Group is reasonably certain to exercise a purchase option, the right-of-use asset is depreciated over the underlying asset's useful life.

Payments associated with short-term leases of office and warehouse are recognised on a straight-line basis as an expense in profit or loss. Short-term leases are leases with a lease term of 12 months or less.

2.24 Dividend distribution

Provision is made for the amount of any dividend declared, being appropriately authorised and no longer at the discretion of the entity, on or before the end of the reporting period but not distributed at the end of the reporting period.

2.25 Interest income

Interest income from financial assets at FVTPL is included in the net fair value gains on these assets, see Note 8 below.

Interest income on financial assets at amortised cost calculated using the effective interest method is recognised in profit or loss as part of finance income.

Interest income is presented as finance income where it is earned from financial assets that are held for cash management purposes, see Note 12 below. Any other interest income is included in finance income.

Interest income is calculated by applying the effective interest rate to the gross carrying amount of a financial asset except for financial assets that subsequently become credit-impaired. For credit-impaired financial assets the effective interest rate is applied to the net carrying amount of the financial asset (after deduction of the loss allowance).

2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

2.26 Government grants

Grants from the government are recognised at their fair value where there is a reasonable assurance that the grant will be received and the Group will comply with all attached conditions.

3 FINANCIAL RISK MANAGEMENT

3.1 Financial risk factors

The Group's activities expose it to a variety of financial risks: market risk (including foreign exchange risk, cash flow interest-rate risks and price risk), credit risk and liquidity risk. The Group's overall risk management programme focuses on the unpredictability of financial markets and seeks to minimise potential adverse effects on the Group's financial performance.

(a) Market risk

(i) Foreign exchange risk

The Group's transactions are mainly denominated in HKD and United States dollars ("USD"). The majority of assets and liabilities are denominated in HKD and USD, and there are no significant assets and liabilities denominated in other currencies.

At 30 June 2020, if USD had strengthened/weakened by 1% against HKD with all other variables held constant, post-tax loss for the year would have been approximately HK\$826,000 higher/ lower (2019: Nil), mainly as a result of the foreign exchange differences on translation of USD denominated cash and bank balances.

(ii) Cash flow interest-rate risks

As the Group has no significant interest-bearing assets, other than short-term bank deposits, the Group's income and operating cash flows are substantially independent of changes in market interest rates.

At 30 June 2020, if interest rates on all interest-bearing bank and cash deposits had been 100 basis points higher/lower with all other variables held constant, post-tax profit for the year would have been approximately HK\$602,000 (2019: HK\$747,000) higher/lower due to interest income earned on market interest rate.

3 FINANCIAL RISK MANAGEMENT (CONTINUED)

3.1 Financial risk factors (Continued)

(a) Market risk (Continued)

(iii) Price risk

The Group's exposure to equity securities price risk arises from investments held by the Group and classified in the consolidated balance sheet as financial assets at fair value through profit or loss (Note 19).

Post-tax profit for the year would increase/decrease by approximately HK\$2,845,000 (2019: Nil) as a result of 10% gains/losses on financial assets classified as at fair value through profit or loss.

(b) Credit risk

(i) Risk Management

Credit risk is managed on a group basis. The carrying amounts of cash and cash equivalents, trade receivables, deposits, other receivables and amounts due from related companies represent the Group's maximum exposure to credit risk in relation to financial assets. The Group has policies that limit the amount of credit exposure to any financial institutions. The Group has also policies in place to ensure that the sales are made to customers with appropriate credit history and the Group performs periodic credit evaluations of its customers.

The Group's cash and cash equivalents are placed with reputable banks and financial institutions. The Group reviews regularly the recoverable amount of deposits, other receivable and amounts due from related companies to ensure that adequate impairment losses are made for irrecoverable amounts.

(ii) Impairment of financial assets

The group has three types of financial assets that are subject to the expected credit loss model:

- Trade receivables; and
- Other financial assets carried at amortised cost.

While cash and cash equivalents are also subject to the impairment requirements of HKFRS 9, the identified impairment loss was immaterial.

3 FINANCIAL RISK MANAGEMENT (CONTINUED)

3.1 Financial risk factors (Continued)

(b) Credit risk (Continued)

(ii) Impairment of financial assets (Continued)

Trade receivables

The Group applies the HKFRS 9 simplified approach to measuring expected credit losses which uses a lifetime expected loss allowance for all trade receivable.

To measure the expected credit losses, trade receivables have been grouped based on shared credit risk characteristics and the days past due. Future cash flows for each group receivables are estimated on the basis of historical loss experience, adjusted to reflect the effects of current conditions as well as forward looking information on macroeconomic factors affecting the ability of the customers to settle the receivables. The expected credit losses for trade receivables are not material.

Other financial assets carried at amortised cost

The Group applies a 12-month expected credit loss on other financial assets at amortised cost. Management considered among other factors, analysed historical pattern and concluded that the expected credit loss for other financial assets at amortised cost to be immaterial as the credit risk is assessed as low.

(c) Liquidity risk

Prudent liquidity management implies maintaining sufficient cash and cash equivalents.

The Group's primary cash requirements have been the payment of service fees to healthcare personnel on behalf of the respective service demanders and operating.

The Group mainly finances its working capital requirements through internal resources.

The Group's policy is to regularly monitor current and expected liquidity requirements to ensure it maintains sufficient cash and cash equivalents to meet its liquidity requirements in the short and long term.

3 FINANCIAL RISK MANAGEMENT (CONTINUED)

3.1 Financial risk factors (Continued)

(c) Liquidity risk (Continued)

The table below analyses the Group's financial liabilities into relevant maturity groupings based on the remaining period at the end of the reporting date to the contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows.

_	Within 1 year HK\$'000	Between 1 and 2 years HK\$'000	Between 2 and 5 years HK\$'000	Total HK\$'000	Carrying amount HK\$'000
At 30 June 2020					
Trade payables	12,750	_	_	12,750	12,750
Accruals and other payables	2,645	-	-	2,645	2,645
Lease liabilities	3,221	2,376	443	6,040	5,759
_	18,616	2,376	443	21,435	21,154
At 30 June 2019					
Trade payables	16,260	_	_	16,260	16,260
Accruals and other payables	3,615	-	-	3,615	3,615
	19,875	_	_	19,875	19,875

3.2 Capital risk management

The Group's objectives when managing capital are to safeguard the Group's ability to continue as a going concern in order to provide returns for shareholders and benefits for other stakeholders and to maintain an optimal capital structure to reduce the cost of capital.

The Group manages the capital structure and makes adjustments to it in light of changes in economic conditions. In order to maintain or adjust the capital structure, the Group may adjust the dividend payments to shareholders, return capital to shareholders and issue new shares.

3 FINANCIAL RISK MANAGEMENT (CONTINUED)

3.3 Fair value estimation

The Group analyses the financial instruments carried at fair value by level of the inputs to valuation techniques used to measure fair value. Such inputs are categorised into three levels within a fair value hierarchy as follows:

- Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
- Level 3: Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

All the Group financial assets at FVTPL are included in Level 1 as at 30 June 2020 (2019: Nil).

There were no transfers of financial assets between levels 1, 2 and 3 during the year.

The carrying amounts of the Group's current financial assets, including cash and cash equivalents, trade receivables, deposits and other receivables and amounts due from related companies; and the Group's current financial liabilities including trade payables, accruals and other payables, and lease liabilities approximate their fair values due to their short maturities.

4 CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS

Estimates and judgements used in preparing consolidated financial statements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities, or the presentation of the consolidated financial statements within the next financial year are discussed below.

Determination of the Group's role as a principal or an agent

The management considers that under the Group's healthcare staffing solution services, it is acting as an agent, taking into account the totality of all relevant attributes underlying the existing service arrangements. The major features that indicate that the Group is acting as an agent include:

Employment relationships between the Group and the healthcare personnel

The terms of agreement with healthcare personnel specify that there is no employment relationship between the Group and the healthcare personnel.

4 CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS (CONTINUED)

Determination of the Group's role as a principal or an agent (Continued)

Contractual exposure

The standard term sheet with customers sets out certain material terms governing the relationship between the Group and the customers, including the terms that the Group will perform a referral service for the customers based on their requested level of qualification of the healthcare personnel subject to the availability of the healthcare personnel which is not guaranteed by the Group, and the terms that the Group does not directly participate in the performance of healthcare services and is not contractually responsible for the conduct, professional expertise or any liability after the commencement of work of healthcare personnel so assigned to the customers.

The management reassesses the Group's position upon any subsequent changes in the existing service arrangements.

5 SEGMENT INFORMATION

The Group is principally engaged in the provision of healthcare staffing solution services to private and institutional customers in which placement of healthcare personnel is made according to the specific request from these customers. The Group is also engaged in provision of outreach case assessment related services and operation of aesthetic clinic.

Management reviews the operating results of the business as one segment to make decisions about resources to be allocated. Therefore, the executive directors of the Company regard that there is only one segment which is used to make strategic decisions. Revenue and profit after income tax are the measures reported to the executive director for the purpose of resources allocation and performance assessment.

The Group primarily operates in Hong Kong and most of its non-current assets are located in Hong Kong. During the year ended 30 June 2020, all revenue was earned from external customers in Hong Kong (2019: Same).

6 REVENUE FROM CONTRACTS WITH CUSTOMERS

	2020 HK\$'000	2019 HK\$'000
	66.000	72.460
Revenue from provision of healthcare staffing solution services	66,898	73,160
Revenue from provision of outreach case assessment related services	4,882	4,736
Revenue from operation of aesthetic clinic	538	568
	72,318	78,464
	2020	2019
	HK\$'000	HK\$'000
Timing of revenue recognition		
– At a point in time	67,436	73,728
– Over time	4,882	4,736
	72,318	78,464

An analysis of the gross components in arriving at the Group's revenue from provision of healthcare staffing solution services is set out below:

	2020 HK\$'000	2019 HK\$'000
Gross fee Cost attributable to healthcare personnel	244,430 (177,532)	269,196 (196,036)
Revenue from provision of healthcare staffing solution services	66,898	73,160

The gross fee does not represent the Group's revenue.

7 OTHER INCOME

	2020	2019
	HK\$'000	HK\$'000
Sales of goods	2,925	738
Government grants	971	_
Advertising income	513	1,303
Rent concession	149	_
Activity income	-	227
Others	679	1,031
	5,237	3,299

8 OTHER GAINS, NET

	2020 HK\$'000	2019 HK\$'000
Net fair value gains on financial assets at FVTPL (Note 19)	1,351	-
Net foreign exchange losses	(483)	_
(Losses)/gains on disposals and write off of property, plant and equipment		
(Note 35)	(257)	115
Gain on deemed disposal of an associate (Note)	-	1,944
Gain on bargain purchase from an acquisition of business (Note)	-	305
Others		(1,270)
	611	1,094

Note:

On 30 April 2019, Achiever Ventures Limited, a wholly-owned subsidiary of the Company, completed an acquisition of the remaining 70% of equity interest in Garden Medical Center Limited ("GMC") from Chan Hau Ngai and Richie Chan Chiu Lung for a total consideration of HK\$4,208,000, represented by cash consideration of HK\$1,210,000 and assignment of the shareholder's loan of HK\$2,998,000.

As at 30 April 2019, the carrying amount of the investment in and advance to GMC was HK\$1,054,000. The gain on deemed disposal of an associate of HK\$1,944,000 represents the difference between the carrying amount of the investment in and advance to GMC and the amount being assigned upon acquisition.

At as the acquisition date, the fair value of GMC was estimated by an independent qualified valuer to be HK\$4,513,000, which gave rise to a fair value gain of HK\$305,000.

9 OTHER EXPENSES

	2020 HK\$'000	2019 HK\$'000
Auditor's remuneration	800	880
Cost of inventories sold	1,973	381
Legal and professional fee	1,585	1,942
Rates and management fee	1,118	1,314
Postage, utilities and general office expenses	1,014	667
Travelling and transportation expenses	1,000	446
Printing costs	521	1,138
Advertising and promotion expenses	514	499
Bank charges	401	233
Insurance expenses	265	265
Entertainment	259	321
Donation	70	66
Management service fee	_	1,899
Other expenses	893	338
	10,413	10,389

10 EMPLOYEE BENEFIT EXPENSES (INCLUDING DIRECTORS' EMOLUMENTS)

	2020 HK\$'000	2019 HK\$'000
Wages, salaries and bonuses	20,010	16,460
Pension costs – defined contribution plan	901	537
Share-based payments to directors and employees	2,537	549
Other staff welfare	603	461
	24,051	18,007

The Group has arranged its Hong Kong employees to join the Mandatory Provident Fund Scheme (the "MPF Scheme"), which is a defined contribution scheme managed by an independent trustee. Under the MPF Scheme, the Hong Kong incorporated subsidiaries of the Group and their Hong Kong employees make monthly contributions to the scheme at 5% of the employees' earnings as defined under the Mandatory Provident Fund legislation. The monthly contributions made by the Group and the employees are subject to a cap of HK\$1,500 each, with contributions beyond these amounts being voluntary.

Contributions to the MPF Scheme charged to the consolidated income statement for the year amounted to approximately HK\$582,000 (2019: HK\$537,000). No forfeited contribution in respect of the defined contribution retirement scheme was utilised during the year (2019: Same). No forfeiture contribution was available as at 30 June 2020 to reduce future contributions (2019: Same). Contributions totaling approximately HK\$55,000 (2019: HK\$49,000) were payable to the MPF Scheme at the year end and were included in accruals and other payables.

The Company's subsidiary in the People's Republic of China ("PRC") is a member of the state-managed retirement benefits scheme operated by the government of the PRC. The retirement benefits scheme contributions of approximately HK\$319,000 (2019: Nil), which are based on a certain percentage of the salaries of the subsidiary's employees, are charged to the consolidated income statement in the period to which they relate and represent the amount of contributions payable by these subsidiary to the scheme.

For both retirement benefits schemes, the Group has no legal or constructive obligation to pay further contributions if the funds do not hold sufficient assets to pay all employees the benefits relating to employee service in the current or prior periods.

11 BENEFITS AND INTERESTS OF DIRECTORS

(a) Directors' and chief executive's emoluments

The remuneration of every director and the chief executive for the year ended 30 June 2020 is set out below:

Emoluments paid to or receivable by directors in respect of a person's services as a director, whether of the Company or its subsidiary undertaking:

							Emoluments	
							paid to or	
							receivable	
							by directors	
							in respect of	
							director's	
						Remunerations	other services	
						paid to or	in connection	
						receivable	with the	
						by directors		
				Allowances	Envelopeda	-	management	
					Employer's	in respect of	of the affairs	
			B 1 (1	and benefits	contribution to	accepting	of the Company	
			Discretionary	in kind	a retirement	office	or its subsidiary	
	Fees	Salaries	bonuses	(Note viii)	benefit scheme	as director	undertaking	Total
_	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000
Executive directors:								
Ms. Hai Hiu Chu								
(Chief executive officer)	-	1,350	290	1,457	18	-	_	3,115
Mr. Woo King Hang (ii)	-	17		-	1	-	_	18
····· ····· ··························								
Independent non-executive								
directors:								
Dr. Ko Wing Man (iii)	165	-	-	-	-	-	-	165
Mr. Wong Kon Man Jason (iv)	165	-	-	124	-	-	-	289
Ms. Chhoa Peck Lim Bella (v)	165	-	-	1	-	-	-	166
Dr. Chan Kai Yue Jason (vi)	165	-	_	1	-	-	-	166
				· ·				
	660	1,367	290	1,583	19		-	3,919

11 BENEFITS AND INTERESTS OF DIRECTORS (CONTINUED)

(a) Directors' and chief executive's emoluments (Continued)

The remuneration of every director and the chief executive for the year ended 30 June 2019 is set out below:

Emoluments paid to or receivable by directors in respect of a person's services as a director, whether of the Company or its subsidiary undertaking:

							Emoluments	
							paid to or	
							receivable	
							by directors	
							in respect of	
							director's	
						Remunerations	other services	
						paid to or	in connection	
						receivable	with the	
						by directors	management	
				Allowances	Employer's	in respect of	of the affairs	
				and benefits	contribution to	accepting	of the Company	
			Discretionary	in kind	a retirement	office	or its subsidiary	
	Fees	Salaries	bonuses	(Note viii)	benefit scheme	as director	undertaking	Total
-	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000
Executive directors:								
Ms. Hai Hiu Chu (Chief executive								
officer)	-	1,800	300	174	18	-	-	2,292
Mr. Woo King Hang (ii)	-	168	-	72	2	-	-	242
Mr. Kwan Chi Hong (i)	-	924	150	-	10	-	-	1,084
Independent non-executive								
directors:								
Dr. Chan Kai Yue Jason (vi)	30	-	-	-	-	-	-	30
Ms. Chhoa Peck Lim Bella (v)	31	-	-	-	-	-	-	31
Dr. Ko Wing Man (iii)	105	-	-	-	-	-	-	105
Mr. Wong Kon Man Jason (iv)	57	-	-	24	-	-	-	81
Mr. Lam Cheng Wai (i)	_	-	-	-	-	-	-	_
Dr. Leung Yu Lung (vii)	89	-	-	_	-	-	-	89
Dr. Luk Yim Fai (i)	62	-	-	-	-	-	-	62
_								

11 BENEFITS AND INTERESTS OF DIRECTORS (CONTINUED)

(a) Directors' and chief executive's emoluments (Continued)

Notes:

- (i) Resigned on 5 January 2019
- (ii) Appointed on 16 May 2019 and resigned on 5 July 2019. The remunerations of Mr. Woo King Hang represent remunerations received from the Group by him in his capacity as an employee to the Group during 16 May 2019 to 30 June 2019.
- (iii) Appointed on 18 August 2018
- (iv) Appointed on 9 January 2019
- (v) Appointed on 28 March 2019
- (vi) Appointed on 1 April 2019
- (vii) Resigned on 28 March 2019
- (viii) Includes housing, travelling allowances and estimated money value of the non-cash benefits share options

No directors waived or agreed to waive any emoluments during the year ended 30 June 2020 (2019: Same).

(b) Five highest paid individuals

The five individuals whose emoluments were the highest in the Group for the year include one (2019: two) director whose emoluments are reflected in the analysis presented in Note 11(a) above. The emoluments payable to the remaining four (2019: three) individuals during the year are as follows:

	2020 HK\$'000	2019 HK\$'000
Basic salaries, bonuses, others allowances and benefits in kind Pension costs – defined contribution plan Share-based payments to employees	3,201 56 918	1,730 52 145
	4,175	1,927
The emoluments fell within the following bands:		
	2020	2019
Emolument bands		
Nil to HK\$1,000,000 HK\$1,000,001 to HK\$2,000,000	2 2	3
	4	3

No emoluments have been paid to the directors of the Company or the highest paid individuals as an inducement to join or upon joining the Company or as compensation for loss of office during the year (2019: Nil).

11 BENEFITS AND INTERESTS OF DIRECTORS (CONTINUED)

(c) Directors' retirement benefits and termination benefits

None of the directors received or will receive any retirement benefits under a defined benefit scheme or termination benefits during the year (2019: Nil).

(d) Consideration provided to third parties for making available directors' services

The Company did not pay consideration to any third parties for making available directors' services during the year (2019: Nil).

(e) Information about loans, quasi-loans and other dealings in favour of directors, controlled bodies corporate by and connected entities with such directors

No loans, quasi-loans and other dealings were made available in favour of directors, controlled body corporate by and connected entities with such directors subsisted at the end of the period or at any time during the year (2019: Nil).

(f) Directors' material interests in transactions, arrangements or contracts

Save as disclosed in Note 34, no significant transactions, arrangements or contracts in relation to the Company's business to which the Company was a party and in which a director of the Company had a material interest, whether directly or indirectly, subsisted at the end of the year or at any time during the year (2019: Nil).

12 FINANCE INCOME AND FINANCE COSTS

	2020	2019
	HK\$'000	HK\$'000
Finance income		
Interest income on bank deposits	1,048	1,087
Finance costs		
Interest expenses on lease liabilities	(326)	_

13 INCOME TAX EXPENSE

Hong Kong profits tax has been provided at the rate of 16.5% (2019: 16.5%) on the estimated assessable profit for the year arising in or derived from Hong Kong. Corporate income tax on profits generated from a subsidiary operating in the PRC has been calculated at 25% in accordance with the relevant PRC tax law and regulations.

	2020	2019	
	HK\$'000	HK\$'000	
Current income tax:			
– Hong Kong profits tax	6,141	8,125	
– PRC corporate income tax	89	_	
– Over provision in prior years	(349)	_	
Deferred income tax (credit)/expense (Note 31)	(395)	73	
Income tax expense	5,486	8,198	

The tax on the Group's profit before income tax differs from the theoretical amount that would arise using the tax rate of Hong Kong, the principal place of the Group's operations, as follows:

	2020 HK\$'000	2019 HK\$'000
Profit before income tax	36,176	47,118
Tax at the applicable tax rate of 16.5% (2019: 16.5%)	5,969	7,774
Effect of progressive rate at 8.25% (2019: 8.25%)	(165)	(165)
Effect of different tax rate in PRC	30	_
Income not subject to tax	(476)	(550)
Expenses not deductible for tax purpose	869	1,011
Utilisation of previoulsy unrecognised tax loss	(382)	_
Tax losses not recognised	30	128
Tax concession	(40)	_
Over provision in prior years	(349)	
	5,486	8,198

14 EARNINGS PER SHARE

Basic earnings per share is calculated by dividing the profit attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the year.

	2020	2019
Profit attributable to equity holders of the Company (HK\$'000)	30,691	38,920
Weighted average number of ordinary shares in issue (thousands)	400,000	400,000
Basic earnings per share (HK cents)	7.67	9.73

Diluted earnings per share for the years were the same as basic earnings per share. During the year ended 30 June 2020, the exercise of the outstanding share options would be anti-dilutive. (2019: Same)

15 DIVIDENDS

On 18 September 2020, the Board resolved to declare a final dividend of HK\$10,000,000 (HK2.50 cents per ordinary share) for the year ended 30 June 2020 to the Company's shareholders whose names appear on the register of members of the Company on 16 November 2020. This proposed dividend is not reflected as dividend payable in these consolidated financial statements.

On 17 February 2020, the Board resolved to declare and pay an interim dividend of HK\$10,000,000 (HK2.50 cents per ordinary share) to the Company's shareholders whose names appear on the register of members of the Company on 2 March 2020.

On 27 September 2019, the Board resolved to declare a final dividend of HK\$20,000,000 (HK5.00 cents per ordinary share) for the year ended 30 June 2019 to the Company's shareholders whose names appear on the register of members of the Company on 22 November 2019.

16 PROPERTY, PLANT AND EQUIPMENT

	Leasehold improvements HK\$'000	Furniture and fixtures HK\$'000	Operating equipment and machinery HK\$'000	Computer equipment HK\$'000	Motor vehicles HK\$'000	Total HK\$'000
At 1 July 2018						
Cost	301	688	_	1,392	1,427	3,808
Accumulated depreciation	(128)	(474)	-	(491)	(1,106)	(2,199)
Net book amount	173	214	-	901	321	1,609
Year ended 30 June 2019						
Opening net book amount	173	214	-	901	321	1,609
Additions	35	70	-	109	-	214
Acquisition from associate to subsidiary	1,404	137	2,337	161	_	4,039
Disposals	-	(64)	-	(16)	(10)	(90)
Depreciation	(260)	(71)	(100)	(159)	(285)	(875)
Closing net book amount	1,352	286	2,237	996	26	4,897
At 30 June 2019						
Cost	1,740	357	2,337	1,550	799	6,783
Accumulated depreciation	(388)	(71)	(100)	(554)	(773)	(1,886)
Net book amount	1,352	286	2,237	996	26	4,897
Year ended 30 June 2020						
Opening net book amount	1,352	286	2,237	996	26	4,897
Adjustment for change in accounting policy (Note 2.2)	(156)					(156)
(NOLE Z.Z)	(150)	-	-	-	-	(150)
Restated as at July 2019	1,196	286	2,237	996	26	4,741
Additions	845	101	1,444	230	-	2,620
Disposals and write off	(34)	-	-	(223)	-	(257)
Depreciation	(980)	(91)	(890)	(247)	(26)	(2,234)
Closing net book amount	1,027	296	2,791	756	-	4,870
At 30 June 2020						
Cost	1,940	458	3,781	1,557	799	8,535
Accumulated depreciation	(913)	(162)	(990)	(801)	(799)	(3,665)
Net book amount	1,027	296	2,791	756	_	4,870

17 LEASES

This note provides information for leases where the Company is a lessee.

(i) Amounts recognised in the consolidated balance sheet

The consolidated balance sheet shows the following amounts relating to leases:

(a) Right-of-use assets

	30 June	1 July
	2020	2019
	HK\$'000	HK\$'000
Office premises	5,096	2,762

Addition to the right-of-use assets during the year ended 30 June 2020 was approximately HK\$5,923,000.

(b) Lease liabilities

	30 June 2020 HK\$'000	1 July 2019 HK\$'000
Current Non-current	3,019 2,740	1,843 883
	5,759	2,726

For adjustments recognised on adoption of HKFRS 16 on 1 July 2019, please refer to Note 2.2.

17 LEASES (CONTINUED)

(ii) Amounts recognised in the consolidated income statement

The consolidated income statement shows the following amounts relating to leases:

	2020 HK\$′000	2019 HK\$'000
Depreciation of right-of-use assets Office premises	3,570	_
Interest expense on lease liabilities (Note 12) Expenses relating to leases of short-term leases	326 1,758	

The total cash outflow for leases for the year ended 30 June 2020 was approximately HK\$4,955,000.

(iii) The Group's leasing activities and how these are accounted for

The Group leases various offices. Rental contracts are typically made for fixed periods of one to three years.

Lease terms are negotiated on an individual basis and contain a wide range of different terms and conditions. The lease agreements do not impose any covenants other than the rental deposits in the leased assets that are held by the lessor. Leased assets were not be used as security for borrowing purposes.

(iv) There are no variable lease payments contain in the leases.

18 INVESTMENT IN A JOINT VENTURE

	2020	2019
	HK\$'000	HK\$'000
Investment to a joint venture	2,500	2,500
Share of losses of a joint venture	(2,150)	(1,464)
Currency translation differences	62	(3)
	412	1,033

Movement of investment in a joint venture are analysed as below:

	2020 HK\$'000	2019 HK\$'000
As at 1 July	1,033	2,245
Share of losses of a joint venture	(686)	(1,207)
Currency translation differences	65	(5)
As at 30 June	412	1,033

Set out below is the joint venture of the Group as at 30 June 2020 and 2019 which, in the opinion of the directors, is material to the Group. The joint venture as listed below has share capital consisting solely of ordinary shares, which are held directly by the subsidiary of the Company. The country of incorporation or registration is also its principal place of business, and the proportion of ownership interest is the same as the proportion of voting rights held.

Nature of investment in a joint venture as at 30 June 2020 and 2019 is as follows:

Name	Place of incorporation	% of ownership interest		Principal activities
		2020	2019	
Bamboos Professional Nursing Services PTE. Limited ("PNS PTE")	Singapore	50%	50%	Healthcare staffing solution services in Singapore

PNS PTE is a private company and there is no quoted market price available for its shares. There are no contingent liabilities relating to the Group's investment in the joint venture.

18 INVESTMENT IN A JOINT VENTURE (CONTINUED)

Summarised financial information for a joint venture

Summarised balance sheet

	2020 HK\$'000	2019 HK\$'000
Current		
Cash and cash equivalents	627	1,785
Other current assets (excluding cash)	56	367
Total current assets	683	2,152
Trade payables	(3)	(101)
Current financial liabilities (excluding trade payables)	(249)	(193)
Total current liabilities	(252)	(294)
Non-current		
Assets	393	742
Liabilities		(534)
Net assets	824	2,066
Summarised statement of comprehensive income		
	2020	2019

	HK\$'000	HK\$'000
Revenue	541	491
Depreciation	(327)	(90)
Loss and total comprehensive loss	(1,372)	(2,414)

18 INVESTMENT IN A JOINT VENTURE (CONTINUED)

Reconciliation of summarised financial information

Reconciliation of the summarised financial information presented to the carrying amount of its investment in a joint venture

	2020 HK\$′000	2019 HK\$'000
Summarised financial information		
Opening net assets	2,066	4,490
Loss for the year	(1,372)	(2,414)
Exchange difference	130	(10)
Closing net assets	824	2,066
Group's share in %	50%	50%
Investment in a joint venture	412	1,033
Carrying amount as at 30 June	412	1,033

19 FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS

(i) Classification of financial assets at fair value through profit or loss

The Group classifies the following financial assets at FVTPL:

- debt investments that do not qualify for measurement at either amortised cost or financial asset at fair value through other comprehensive income;
- equity investments that are held for trading; and
- equity investments for which the entity has not elected to recognise fair value gains and losses through other comprehensive income.

19 FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS (CONTINUED)

(i) Classification of financial assets at fair value through profit or loss (Continued)

Financial assets mandatorily measured at FVTPL include the following:

	2020 HK\$'000	2019 HK\$'000
Non-current assets		
Listed bonds	15,416	_
Listed equity securities	13,033	
	28,449	

See Note 2.10 for the remaining relevant accounting policies.

(ii) Amounts recognised in profit or loss

During the year, the following gains/(losses) were recognised in profit or loss:

	2020 HK\$'000	2019 HK\$'000
Fair value gains on debt instruments at FVTPL recognised		
in other gains, net (Note 8) Fair value loss on investment funds at FVTPL recognised	2,229	_
in other gains, net (Note 8) Fair value losses on equity instruments at FVTPL recognised	(852)	_
in other gains, net (Note 8)	(26)	
	1,351	_

(iii) Risk exposure and fair value measurements

Information about the Group's exposure to price risk is provided in Note 3.1(a)(iii). For information about the methods and assumptions used in determining fair value refer to Note 3.3.

20 FINANCIAL INSTRUMENTS BY CATEGORY

	2020 HK\$'000	2019 HK\$'000
Financial assets at amortised cost		
Trade receivables (Note 21)	24,240	41,426
Deposits and other receivables (Note 23)	14,995	10,635
Amounts due from related companies (Note 24)	249	892
Cash and cash equivalents (Note 25)	101,633	118,703
	141,117	171,656
Financial assets at FVTPL		
Financial assets at FVTPL (Note 19)	28,449	
Financial liabilities at amortised costs		
Trade payables (Note 29)	12,750	16,260
Accruals and other payables	2,645	3,615
Lease liabilities (Note 17)	5,759	
	21,154	19,875

The Group's exposure to various risks associated with the financial instruments is discussed in Note 3. The maximum exposure to credit risk at the end of the reporting period is the carrying amount of each class of financial assets mentioned above.

21 TRADE RECEIVABLES

	2020 HK\$'000	2019 HK\$'000	
bles	24,240	41,426	

The carrying amounts of trade receivables are denominated in Hong Kong dollars.

As at 30 June 2020, balances due from the top five customers accounted for 37% (2019: 29%) of the total balances. There is no concentration of credit risk with respect to trade receivables as there is a dispersed number of independent customers. The directors consider that the credit risk in respect of these customers is currently low after considering past experience with these customers.

21 TRADE RECEIVABLES (CONTINUED)

The Group's trade receivables had no credit term and payment was immediately due upon presentation of invoices to customers. As at 30 June 2020 and 2019, all trade receivables were past due but not considered to be impaired because these mainly related to a number of customers with limited history of default. The ageing analysis of trade receivables by the date on which the respective sales invoices were issued was as follow:

	2020 HK\$′000	2019 HK\$'000
Less than 61 days	20,539	33,041
61 to 90 days	2,034	4,630
91 to 180 days	885	1,827
Over 180 days	782	1,928
	24,240	41,426

The credit quality of trade receivables past due but not impaired has been assessed by reference to historical information about the counterparty default rates. The existing counterparties do not have significant defaults in the past.

As at 30 June 2020 and 2019, no collateral has been received from these counterparties.

22 INVENTORIES

	2020	2019
	HK\$'000	HK\$'000
Trading merchandise	930	947

Cost of inventories sold recognised as expenses and included in "other expenses" amounted to approximately HK\$1,973,000 (2019: HK\$381,000).

23 PREPAYMENTS, DEPOSITS AND OTHER RECEIVABLES

	2020 HK\$'000	2019 HK\$'000
Current		1 2 2 5
Prepayments	467	1,206
Deposits Other receivables	3,648 238	3,779 729
	4,353	5,714
Non-current		
Prepayment	335	1,272
Deposits	11,109	6,127
	11,444	7,399
Total	15,797	13,113

The carrying amounts of prepayments, deposits and other receivables of the Group are denominated in following currencies.

	2020	2019
	HK\$'000	HK\$'000
	·	
НКД	15,682	13,113
Renminbi ("RMB")	115	_
	15,797	13,113

24 AMOUNTS DUE FROM RELATED COMPANIES

	2020 HK\$'000	2019 HK\$′000
		UV \$ NU
Bamboos Professional Nursing Services PTE. Limited	-	102
Bamboos Limited	-	25
Bamboos Education School For Talents Limited	25	321
The Hong Kong Health Care Federation Limited	224	444
	249	892

The maximum outstanding receivable balance during the year is as follows:

	2020 HK\$'000	2019 HK\$'000
Bamboos Professional Nursing Services PTE. Limited	102	102
Bamboos Limited	25	25
Bamboos Education School For Talents Limited	321	321
The Hong Kong Health Care Federation Limited	444	444

The amounts due from related companies are unsecured, interest-free, repayable on demand and denominated in Hong Kong dollars.

25 CASH AND BANK BALANCES

	2020 HK\$'000	2019 HK\$'000
Cash at banks Bank deposits	41,364 60,233	43,930 74,741
Cash on hand	36	32
Total cash and cash equivalents	101,633	118,703
Maximum exposure to credit risk	101,597	118,671

The effective interest rate on the bank deposits was 1% per annum (2019: 1% per annum). These deposits had original maturity of three months or less.

25 CASH AND BANK BALANCES (CONTINUED)

The carrying amounts of the cash and bank balances are denominated in following currencies:

2020 HK\$′000	2019 HK\$'000
17,596	118,703
83,492	-
545	
101,633	118,703

26 SHARE CAPITAL AND SHARE PREMIUM

Share capital

	Number of shares	Ordinary shares of HK\$0.01 each HK\$'000
Authorised: At 1 July 2018, 30 June 2019 and 30 June 2020	2,000,000,000	20,000
Issued and fully paid: At 1 July 2018, 30 June 2019 and 30 June 2020	400,000,000	4,000
Sharo promium		

Share premium

	2020 HK\$′000	2019 HK\$'000
ne 2020	39,123	39,123

Information relating to the share option, including details of options issued, exercised and lapsed during the financial year and options outstanding at the end of the reporting period, is set out in Note 28.

27 RESERVES

Movement in reserves of the Group are set out in the consolidated statement of changes in equity in page 70.

28 SHARE-BASED PAYMENTS

The Company has a share option scheme approved and adopted on 24 June 2014 ("Share Option Scheme"), pursuant to which share options may be granted to directors (including executive, non-executive or independent non-executive directors) and any employee (full-time or part-time) of the Group (on an employment or contractual or honorary basis and paid or unpaid) to subscribe for the shares of the Company, subject to a maximum of 10% of the total number of shares in issue as at the listing date or such maximum number as approved by the shareholders.

The Share Option Scheme is valid and effective for a period of ten years commencing on the adoption date of the scheme.

The exercise price shall be at least the highest of (i) the closing price of the Company's shares as stated in the Stock Exchange's daily quotations sheet on the date of grant of the option, which must be a business day; (ii) the average of the closing prices of the shares as stated in the Stock Exchange's daily quotations sheets for the five consecutive business days immediately preceding the date of grant of the option; and (iii) the nominal value of the share on the date of grant of the option.

Set out below are summaries of options granted under the plan:

	2020		201	1	
	Average		Average		
	exercise price		exercise price		
	in HK\$ per	Number of	in HK\$ per	Number of	
	share option	options	share option	options	
As at 1 July	1.440	6,800,000	-	-	
Granted during the year	0.994	10,000,000	1.440	8,000,000	
Forfeited during the year	1.344	(1,390,000)	1.440	(1,200,000)	
As at 30 June	1.159	15,410,000	1.440	6,800,000	

As at 30 June 2020, 2,469,000 options out of the 15,410,000 outstanding options were exercisable (2019: Nil).

28 SHARE-BASED PAYMENTS (CONTINUED)

Share options outstanding as at 30 June 2020 and 2019 have the following expiry dates and exercise prices:

			2020	2019
		Exercise price in	Number of	Number of
Grant date	Expiry date	HK\$ per share option	options	options
29 April 2019	29 April 2029	1.440	5,710,000	6,800,000
26 June 2020	26 June 2030	0.994	9,700,000	_
		-		
		_	15,410,000	6,800,000
Weighted average rem	aining contractual life of opt	tions	9.57 years	9.84 years

outstanding at the end of the year

The assessed fair value at grant date of options granted during the year ended 30 June 2020 was HK\$0.33 (2019: HK\$0.68) per option. The fair value at grant date is independently determined using an adjusted form of the Black Scholes Model which includes a Monte Carlo simulation model that takes into account the exercise price, the term of the option, the impact of dilution (where material), the share price at grant date and expected price volatility of the underlying share, the expected dividend yield, the risk free interest rate for the term of the option and the correlations and volatilities of the peer group companies.

The model inputs for options granted during the year ended 30 June 2020 and 2019 included:

- (a) vested options are exercisable for a period of seven to nine years after vesting (2019: Same)
- (b) exercise price: HK\$0.994 (2019: HK\$1.440)
- (c) grant date: 26 June 2020 (2019: 29 April 2019)
- (d) expiry date: 26 June 2030 (2019: 29 April 2029)
- (e) share price at grant date: HK\$0.980 (2019: HK\$1.440)
- (f) expected price volatility of the company's shares: 46% (2019: 52%)
- (g) expected dividend yield: 3.09% (2019: 1.74%)
- (h) risk-free interest rate: 0.65% (2019: 1.67%)

The expected price volatility is based on the historic volatility (based on the remaining life of the options), adjusted for any expected changes to future volatility due to publicly available information.

29 TRADE PAYABLES

Payment term with majority of the healthcare personnel is 30 days.

The ageing analysis of trade payables based on invoice date was as follows:

	2020	2019
	HK\$'000	HK\$'000
	· · · ·	
Less than 31 days	12,750	16,149
31 to 60 days	-	53
61 to 90 days	-	58
	12,750	16,260
	12,750	

The carrying amounts of trade payables are denominated in Hong Kong dollars.

30 ACCRUALS AND OTHER PAYABLES

	2020 HK\$'000	2019 HK\$'000
Accrued expenses Other payables	1,954 1,635 861	3,103 1,270
Contract liabilities	4,450	4,666

The carrying amounts of accruals and other payables are denominated in following currencies:

	2020 HK\$′000	2019 HK\$'000
łKD	4,274	4,666
RMB	176	
	4,450	4,666

31 DEFERRED INCOME TAX

Deferred taxation is calculated in full on temporary differences under the liability method using a principal taxation rate of 16.5% (2019: 16.5%). The movement on deferred income tax assets/(liabilities) in respect of accelerated/ decelerated tax depreciation is as follows:

	2020	2019
	HK\$'000	HK\$'000
At 1 July	(192)	(119)
Credited/(charged) to profit or loss (Note 13)	395	(73)
At 30 June	203	(192)

Deferred income tax assets are recognised for deductible temporary differences to the extent that the realisation of the related tax benefits through future taxable profits is probable.

As at 30 June 2020, the Group had cumulative tax losses of approximately HK\$6,197,000 (2019: HK\$7,266,000), that are available for offset against future taxable profits of the companies in which the losses arose, for which deferred tax assets of approximately HK\$1,022,000 (2019: HK\$1,199,000) were not recognised due to uncertainty of their recoverability. As at 30 June 2020, the tax losses of approximately HK\$6,197,000 (2019: HK\$7,266,000), can be carried forward indefinitely under the current tax legislation.

32 BANKING FACILITIES

At 30 June 2020, the banking facilities amounting to approximately HK\$150,210,000 (2019: Nil) are made available to the Group and unutilised.

33 COMMITMENTS

(a) Capital commitment

	2020 HK\$'000	2019 HK\$'000
Capital injection to PNS PTE contracted but not yet incurred	2,500	2,500
Intangible asset contracted but not provided for	543	_
Property, plant and equipment contracted but not provided for		350

(b) Operating lease commitments

The Group leases offices under non-cancellable operating lease agreements. The lease terms are generally within three years.

The future aggregate minimum lease payments under non-cancellable operating leases are as follows:

	2020	2019
	HK\$'000	HK\$'000
No later than 1 year	-	4,907
Later than 1 year and no later than 5 years	-	1,046
	-	5,953

From 1 July 2019, the Group has recognised right-of-use assets for these leases, except for short-term leases, see Note 17 for further information.

34 RELATED PARTY TRANSACTIONS

Parties are considered to be related if one party has the ability, directly or indirectly, to control the other party or exercise significant influence over the other party in making financial and operating decisions. Parties are also considered to be related if they are subject to common control. During the year, except for The Hong Kong Health Care Federation Limited (being an entity in which Ms. Hai Hiu Chu individually hold directorship), the equity interests of all other related parties involving in transactions or having balances with the Group are controlled by Ms. Hai Hiu Chu.

(a) Year-end balances

As at 30 June 2020 and 2019, apart from those balances disclosed in Note 24, the Group also has following deposits placed with related companies:

	2020	2019
	HK\$'000	HK\$'000
Rental and management fee deposit to Bamboos Group Limited		1,274

(b) Transactions with related parties

During the year, the Group had the following significant transactions with its related parties:

	2020	2019
	HK\$'000	HK\$'000
Operating lease rental to Bamboos Group Limited	1,600	4,800
Management fee to Bamboos Group Limited	394	1,116

Operating lease rental is charged in accordance with the agreement entered into between the relevant parties, whereas those transactions with related companies are entered into at terms mutually agreed between the relevant parties.

(c) Key management compensation

The emoluments of the key management include one executive director (2019: two) whose emoluments are disclosed in Note 11(a).

35 NOTE TO CONSOLIDATED STATEMENT OF CASH FLOWS

(a) Reconciliation of profit before income tax to cash generated from operations

	2020 HK\$'000	2019 HK\$'000
Cash flow from operating activities		
Profit before income tax	36,176	47,118
Adjustments for:		
 Depreciation of property, plant and equipment 	2,234	875
 Depreciation of right-of-use assets 	3,570	_
- Losses/(gains) on disposals and write off of property, plant and		
equipment	257	(115)
– Interest income	(1,048)	(1,087)
– Interest expenses	326	-
- Gain on bargain purchase from acquisition of business	-	(305)
- Gain on deemed disposal of an associate	-	(1,944)
 Share of losses of an associate and a joint venture 	686	2,137
 Share-based payments to directors and employees 	2,537	549
– Net fair value gains on financial assets at FVTPL	(1,351)	
	43,387	47,228
Changes in working capital:		
– Trade receivables	17,186	2,798
 Prepayments, deposits and other receivables 	(2,684)	(6,730)
- Balances with related companies	643	(882)
 Trade payables, accruals and other payables 	(3,606)	(2,040)
– Inventories	17	(48)
Cash generated from operations	54,943	40,326

35 NOTE TO CONSOLIDATED STATEMENT OF CASH FLOWS (CONTINUED)

(b) In the consolidated statement of cash flows, proceeds from disposals and write off of property, plant and equipment comprise:

	2020	2019
	HK\$'000	HK\$'000
Net book amount (Note 16) (Losses)/gains on disposals and write off of property,	257	90
plant and equipment (Note 8)	(257)	115
Proceeds from disposals of property, plant and equipment		205

(c) Reconciliation of liabilities arising from financing activities

	Lease liabilities HK\$'000
At 1 July 2019	_
Recognised on adoption of HKFRS 16 (Note 2.2)	2,726
Restated as at 1 July 2019	2,726
Additions	5,923
Cash flows	(2,871)
Currency translation differences	(19)
At 30 June 2020	5,759

36 BALANCE SHEET AND RESERVES MOVEMENTS OF THE COMPANY

	2020 HK\$′000	2019 HK\$'000
ASSETS		
Non-current assets		
Investments in subsidiaries	21,070	17,804
Current assets		
Prepayments and other receivables	129	165
Amounts due from subsidiaries	14,600	24,677
Cash and cash equivalents	39,299	38,842
	54,028	63,684
Total assets	75,098	81,488
EQUITY AND LIABILITIES		
Capital and reserves attributable to equity holders of the Company		
Share capital	4,000	4,000
Share premium	39,123	39,123
Reserve (Note (a))	29,881	37,277
Total equity	73,004	80,400
Current liabilities		
Accruals and other payables	87	308
Amounts due to subsidiaries	2,007	780
Total liabilities	2,094	1,088
Total equity and liabilities	75,098	81,488

The balance sheet of the Company was approved by the Board of Directors on 18 September 2020 and was signed on its behalf.

Hai Hiu Chu Director

36 BALANCE SHEET AND RESERVES MOVEMENTS OF THE COMPANY (CONTINUED)

Note (a): Reserves movements of the Company

	Contributed surplus	Share-based compensation reserve	Retained earnings	Total
	HK\$'000	HK\$'000	HK\$'000	HK\$'000
Balance at 1 July 2018	16,672	_	11,189	27,861
Profit for the year		_	18,867	18,867
Employee share scheme (Note 28)	-	549	_	549
2018 final dividend		_	(10,000)	(10,000)
Balance at 30 June 2019 and 1 July 2019	16,672	549	20,056	37,277
Profit for the year	-	-	20,067	20,067
Employee share scheme (Note 28)	-	2,537	-	2,537
2019 final dividend	-	-	(20,000)	(20,000)
2020 interim dividend		-	(10,000)	(10,000)
Balance at 30 June 2020	16,672	3,086	10,123	29,881

37 PARTICULARS OF PRINCIPAL SUBSIDIARIES

Details of the principal subsidiaries at 30 June 2020 and 2019 is as follows:

	Place of incorporation	Principal activities	lssued share capital/		
Name of company	and kind of legal entity	and place of operation	registered capital		st held
				2020	2019
Directly held					
Achiever Team Limited	BVI, limited liability company	Investment holding	10 Ordinary shares	100%	100%
Achiever Empire Limited	BVI, limited liability company	Investment holding	1 Ordinary share	100%	100%
Achiever Matrix Limited	BVI, limited liability company	Investment holding	1 Ordinary share	100%	100%
Achiever Ventures Limited	BVI, limited liability company	Investment holding	1 Ordinary share	100%	100%
Achiever Vantage Limited	BVI, limited liability company	Investment holding	1 Ordinary share	100%	100%
Ocean Force Limited	BVI, limited liability company	Investment holding	50,000 Ordinary shares	100%	100%
Achiever Voyage Limited	BVI, limited liability company	Investment holding	50,000 Ordinary shares	100%	100%
Indirectly held					
Bamboos Professional Nursing Services Limited	Hong Kong, limited liability company	Healthcare staffing solution services in Hong Kong	100 Ordinary shares	100%	100%
Bamboos FinTech Limited	Hong Kong, limited liability company	Investment holding	1 Ordinary share	100%	100%
Bamboos Marketing and Consulting Limited	Hong Kong, limited liability company	Marketing and consulting services in Hong Kong	1 Ordinary share	100%	100%
Garden Medical Centre Limited	Hong Kong, limited liability company	Operation of aesthetic clinic in Hong Kong	5,000 Ordinary shares	100%	100%
Eager PacMan Technology Limited	Hong Kong, limited liability company	Investment holding	10,000 Ordinary shares	100%	100%
Bamboos Health Care Holdings (China) Limited	Hong Kong, limited liability company	Dormant	1 Ordinary shares	100%	N/A
Bamboos Health Management Limited	Hong Kong, limited liability company	Dormant	10,000 Ordinary shares	70%	N/A
廣州易嘉柏科技有限公司	PRC, limited liability company	Technology promotion and application services in PRC	Registered capital RMB100,000	100%	100%

The above table sets out the subsidiaries of the Group which, in the opinion of the directors, principally affected the results or assets of the Group.

38 CONTINGENT LIABILITY

A claim was lodged by GMC, a wholly-owned subsidiary of the Group, in June 2019 asserting that the founder and ex-director of GMC (the "defendant") has breached certain clauses in an employment agreement. The defendant has filed a defense and counterclaim in relation to the case for the reliefs to recover the compensation of employee. The matter is currently being considered by the court and the date of hearing has not been scheduled. The Group considers the litigation is on early stage, the evidences are not sufficient for the judgement, therefore no provision is recognised in relation to this claim.

Financial Summary

	For the year ended 30 June				
	2020	2019	2018	2017	2016
-	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000
Results					
Revenue	72,318	78,464	81,359	62,476	50,966
Profit for the year attributable to equity holders of the Company	30,691	38,920	42,221	32,611	26,842
Dividend	20,000	20,000	10,000	35,000	10,000
	2020	2019	As at 30 June 2018	2017	2016
-	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000
Assets and liabilities					
Total assets	181,879	181,011	152,251	124,731	102,257
Total liabilities	(28,606)	(31,030)	(31,734)	(26,437)	(21,574)
Total equity	153,273	149,981	120,517	98,294	80,683

Note:

The summary above does not form part of the audited consolidated financial statements.

關懷備至·專業實幹·全心全意 Care·Competence·Commitment